

Author Index

- Adamopoulos S, *see* Coats, 685
Ahlnér J, *see* Torfgård, 701
Alfieri O, *see* Ferrari, 371
Almkvist H, *see* Thulin, 845
Amery A, *see* Lijnen, 509
Anderson RH, Becker AE (eds). *The Heart: Structure in Health and Disease*, 517
Archer S, *see* Thadani, 199
Arosio E, Pancera P, Sheiban I, Priante F, Riboli M, De Marchi S, Montresor G, Lechi A. Modifications in Peripheral Hemodynamics and Left Ventricular Function in Hypertensives Treated with Nicardipine Slow Release, 167
Asano S, *see* Kira, 251
Asanagi M, *see* Moritani, 749
Aupetit J-F, *see* Timour, 877

Bachetti T, *see* Ferrari, 565
Biraldi P, *see* Modena, 153
Barnett DB, *see* Cowley, 829
Bartels GL, *see* Venneker, 211
Bassenge E. Coronary Vasomotor Responses: Role of Endothelium and Nitrovasodilators, 601
Battler A, *see* Hasdai, 589
Bauer JA, *see* Fung, 489
Bayes-de-Luna A, Vinolas X, Guindo J, Bayes-Genis A. Risk Stratification after Myocardial Infarction: Role of Electrical Instability, Ischemia, and Left Ventricular Function, 335
Bayes-Genis A, *see* Bayes-de-Luna, 335
Becker AE, *see* Anderson, 517
Beil AH, Schmieder RE, Messerli FH. Salt Intake, Blood Pressure, and Cardiovascular Structure, 425
Benedict CR, *see* Pouleur, 313
Berglund L, *see* Thulin, 845
Bernocchi P, *see* Ferrari, 565
Berra P, *see* Ferrari, 371
Besse S, Delcayre C, Chevalier B, Hardouin S, Heymes C, Bourgeois F, Moalik J-M, Swynghedauw B. Is the Senescent Heart Overloaded and Already Failing? 581
Bexton RS, *see* Cowley, 829
Biscione F, *see* Santarelli, 653
Björnsson T, *see* Thulin, 845
Bogaert MG. Clinical Pharmacokinetics of Nitrates, 693
Bolognesi R, *see* Ferrari, 565
Boraso A, *see* Ferrari, 565
Bormann G, *see* Zierhut, 235
Bourgeois F, *see* Besse, 581
Boyle R, *see* Cowley, 829

Bruschke AVG, *see* van der Wall, 345
Bucca V, *see* Di Pasquale, 875
Buikema H, *see* van Veldhuisen, 245

Caccese P, *see* De Caprio, 735
Camacho-Vázquez C, *see* de Teresa, 837
Camichi P, Marraccini P, Gistri R, Salvadori P, Sorace O, L'Abbate A. Andrenergically-Mediated Coronary Vasoconstriction in Patients with Syndrome X, 221
Camici PG, *see* Gistri, 169
Campbell RWF. Post-Infarct Heart Failure: What to Do in Addition to ACE Inhibition, 115
Canter D, *see* Miller, 271
Cats V Manger, *see* van der Wall, 345
Ceconi C, *see* Ferrari, 371
Chalmers JP, *see* van Zweiten, 787
Chevalier B, *see* Besse, 581
Chevrel G, *see* Timour, 877
Chin JC, *see* van der Wall, 345
Choudhury L, *see* Gistri, 169
Christen MO, *see* Ernsberger, 27
Chrysant S, *see* Thadani, 199
Cicatiello AM, *see* De Caprio, 735
Coats AJS, Adamopoulos S, Neurohormonal Mechanisms and the Role of Angiotensin-Converting Enzyme (ACE) Inhibitors in Heart Failure, 685
Cohen MV, *see* Liu, 881
Cohn JN. Treatment of Infarct Related Heart Failure: Vasodilators Other than ACE Inhibitors, 119
Collins LA, *see* Ernsberger, 27
Copen D, *see* Thadani, 199
Cosenz A, Waltman FL, van Es PN, de Leeuw PW. Doxazosin Versus Nitrendipine: A Double-Blind Comparative Study in Patients Adhering to a Sodium-Restricted Diet, 473
Cowley AJ, McEntegart DJ, Hampton JR, Barnett DB, Bexton RS, Boyle R, Hanley SP, Millar-Craig M, Morris GK, Nicholls AJ, Nicholls DP, Oakley GDG, Thomas RD, Ward C, Wynne RD. Long-Term Evaluation of Treatment for Chronic Heart Failure: A 1 Year Comparative Trial of Flosequinap and Captopril, 829
Cruickshank JM. J-Curve in Antihypertensive Therapy—Does it Exist? A Personal Point of View, 757
Cruickshank JM, *see* Dollery, 279
Cucchinelli F, *see* Ferrari, 565

Danish Study Group on Verapamil in Myocardial Infarction, *see* Jespersen, 823

Dargie H, *see* Ray, 433
De Caprio L, De Rossi ML, Di Palma A, Lirato C, Caccese P, Sestito M, Lastoria S, Cicatiello AM, Rengo F. Regression of Left Ventricular Hypertrophy and Improvement of Renal Hemodynamics in Hypertensive Patients Treated With Quinapril, 735
de Geest H, *see* Zmudka, 479
de Giuli F, *see* Ferrari, 371
de Graeff P, *see* van Veldhuisen, 245
Delcan JL, *see* Lopez-Sendon, 393
Delcayre C, *see* Besse, 581
de Leeuw PW, *see* Cosenz, 473
De Marchi S, *see* Arosio, 167
Demopoulos L, LeJemtel TH. Peripheral Factors in the Management of Congestive heart Failure, 75
De Rossi ML, *see* De Caprio, 735
de Sa E Lopez, *see* Lopez-Sendon, 393
de Smet B, *see* van Veldhuisen, 245
de Teresa E, González M, Camacho-Vázquez C, Tabuenca MJ. Effects of Bisoprolol on Left Ventricular Hypertrophy in Essential Hypertension, 837
De Palma A, *see* De Caprio, 735
Di Pasquale P, Paterna S, Bucca V, Licata G. Effects of Administration of Captopril, Metoprolol and the Captopril-metoprolol Combination as Adjvant Therapy during Thrombolysis in Acute Myocardial Infarction, 875
Dollery CT, Frishman WH, Cruickshank JM. Review of "Current Cardiovascular Drugs, 1st Edition," 279
Dominiak P. Historic Aspects in the Identification of the I_1 Receptor and the Pharmacology of Imidazolines, 21
Downey JM, *see* Liu, 881
Dreshaj I, *see* Ernsberger, 27
Dubiel J, *see* Zmudka, 479
Dupuis J. Nitrates in Congestive Heart Failure, 501

Ebert A Genovesi, *see* Gistri, 169
Endo H, Shiraishi H, Yanagisawa M. Afterload Reduction by Hydralazine in Children with Ventricular Septal Defect as Determined by Aortic Input Impedance, 161
Enopras R, Opie LH. Effect of the Angiotensin-Converting Enzyme Inhibitor, Perindopril, and of Angiotensin-II on the Transient Inward Current of Rabbit Ventricular Myocytes, 647

- Ernsberger P, Haxhiu MA, Graff LM, Collins LA, Dreshaj I, Grove DL, Graves ME, Schafer SG, Christen MO. A Novel Mechanism of Action for Hypertensive Control: Moxonidine as a Selective I_1 -Imidazoline Agonist, 27
- Fabrizio L, Regan TJ. Alcoholic Cardiomyopathy, 89
- Fagher B, *see* Thulin, 845
- Fasoli G, *see* Scognamiglio, 319
- Faucon G, *see* Timour, 877
- Fein FS, Sonnenblick EH. Diabetic Cardiomyopathy, 65
- Ferrari R, Cucchinelli F, Bolognesi R, Bachetti T, Boraso A, Bernocchi P, Gaia G, Visioli O. How Do Calcium Antagonists Differ in Clinical Practice? 565
- Ferrari R, La Canna G, Giubbini R, Milani E, Ceconi C, de Giuli F, Berra P, Alfieri O, Visioli O. Left Ventricular Dysfunction due to Stunning and Hibernation in Patients, 371
- Flameng W, *see* Zmudka, 479
- Fox K, *see* Holdright, 193
- Fox K, *see* Purcell, 727
- Fragakis N, *see* Kyriakides, 775
- Frishman WH, *see* Dollery, 279
- Frohlich ED (ed), *see* Kotchen, 279
- Fujiwara R, Hayashi T, Nakai T, Miyamoto S. Diltiazem Inhibits DNA Synthesis and Ca^{2+} Uptake Induced by Insulin, IGF-I, and PDGF in Vascular Smooth Muscle Cells, 861
- Fukasawa M, *see* Orita, 129
- Fukasawa M, *see* Orita, 851
- Fukui K, *see* Orita, 129, 851
- Fung H-L, Bauer JA. Mechanisms of Nitrate Tolerance, 489
- Gaia G, *see* Ferrari, 565
- Gasser RNA, Klein W. Contractile Failure in Early Myocardial Ischemia: Models and Mechanisms, 813
- Gheorghiade M, *see* Tauke, 761
- Ghosh S, *see* Singh, 569
- Giles T, *see* Thadani, 199
- Girbes A, *see* van Veldhuisen, 245
- Gistri R, Ebert A Genovesi, Palombo C, Marabotti C, Choudhury L, Camici PG. Effect of Blood Pressure Lowering on Coronary Vasodilator Reserve in Arterial Hypertension, 169
- Gistri R, *see* Camici, 221
- Giubbini R, *see* Ferrari, 371
- Gmerek A, *see* Miller, 271
- Godfraind T. Cardioselectivity of Calcium Antagonists, 353
- González M, *see* de Teresa, 837
- Gorwit J, *see* Thadani, 199
- Graff LM, *see* Ernsberger, 27
- Graves ME, *see* Ernsberger, 27
- Grove DL, *see* Ernsberger, 27
- Guindo J, *see* Bayes-de-Luna, 335
- Hagerup L, *see* Vaage-Nilsen, 147
- Hampton JR, *see* Cowley, 829
- Han D, *see* Tauke, 761
- Hanley SP, *see* Cowley, 829
- Hansen J Fischer. Review of Postinfarct Treatment with Verapamil, 543
- Hansen J Fischer, *see* Vaage-Nilsen, 147
- Hardouin S, *see* Besse, 581
- Harris P. The Problem of Defining Heart Failure, 477
- Hasdai D, Kornowski R, Battler A. Endothelin and Myocardial Ischemia, 589
- Hasegawa J, Mashiba H. Transient Sexual Dysfunction Observed during Antiarrhythmic Therapy by Long-Acting Disopyramide in a Male Wolff-Parkinson-White Patient, 277
- Hashimoto E, *see* Kira, 251
- Hashimoto K, *see* Nakae, 137
- Haxhiu MA, *see* Ernsberger, 27
- Hayashi T, *see* Fujiwara, 861
- Hayashida W, *see* Eyll C, Rousseau MF, Pouleur H. Effects of Ranolazine on Left Ventricular Regional Diastolic Function in Patients with Ischemic Heart Disease, 741
- Henningsen N, *see* Thulin, 845
- Heymes C, *see* Besse, 581
- Heyndrickx GR, *see* Melin, 381
- Hirooka S, *see* Orita, 129, 851
- Hobbs S, *see* Thadani, 199
- Hof R, *see* Zierhut, 235
- Holdright D, Sparrow J, Wright C, Steiner J, Fox K. Effect of Acadesine, a New Metabolic Agent, on Exercise-Induced Myocardial Ischemia in Chronic Stable Angina, 193
- Hollander NH, *see* Vaage-Nilsen, 147
- Honkavaara M, *see* Thulin, 845
- Iliodromitis E, *see* Kyriakides, 775
- Itakura A, *see* Saida, 365
- Iteld B, *see* Thadani, 199
- Jespersen CM, Danish Study Group on Verapamil in Myocardial Infarction. Role of Ischemia in Post Infarction Heart Failure: Hypothetical Considerations Based on the Use of Verapamil in the DAVIT II Study, 823
- Jones PH. Low Serum Cholesterol Increases the Risk of Noncardiovascular Events: An Antagonist Viewpoint, 871
- Jugdutt BI. Nitrates in Myocardial Infarction, 635
- Julius S. Abnormalities of Autonomic Nervous Control in Human Hypertension, 11
- Kajiyama K, *see* Koga, 83
- Kaplan NH. Comments on Robertson's Critical Review, 673
- Kaplinsky E. Significance of Left Ventricular Hypertrophy in Cardiovascular Morbidity and Mortality, 549
- Kinoshita M, *see* Nakae, 137
- Kira Y, Nakaoaka T, Hashimoto E, Okabe F, Asano S, Sekine I. Effect of Long-Term Cyclic Mechanical Load on Protein Synthesis and Morphological Changes in Cultured Myocardial Cells from Neonatal Rat, 251
- Klein W, *see* Gasser, 813
- Koga Y, Toshima H, Tanaka M, Kajiyama K. Therapeutic Management of Dilated Cardiomyopathy, 83
- Kohi M, *see* Orita, 129
- Kornowski R, *see* Hasdai, 589
- Kotchen TA, Frohlich ED (ed). Review of "Advances in Hypertension 1993," 279
- Krauss XH, *see* Venneker, 211
- Kremastinos DT, *see* Kyriakides, 775
- Krijssen D, *see* Venneker, 211
- Kyriakides ZS, Markianos M, Iliodromitis E, Tsipras D, Fragakis N, Kremastinos DT. Peripheral Vein Plasma Endothelin-1 Levels During Coronary Angioplasty Increase Only in Normotensive Patients, 775
- L'Abbate A, *see* Camici, 221
- La Canna G, *see* Ferrari, 371
- Lamers J, *see* Sassen, 179
- Lamers JMJ, *see* Sharma, 461
- Lanza GA, *see* Santarelli, 653
- Lastorini S, *see* De Caprio, 735
- Lechi A, *see* Arosio, 167
- Leikola-Pelto T, *see* Lilleberg, 263
- Le Jemtel TH, *see* Demopoulos, 75
- Lévy S. Amiodarone as a First-Line Drug in the Treatment of Atrial Fibrillation: The Protagonist Viewpoint, 769
- Lewis BS, Poole-Wilson PA (DEFIANT Study Group). The DEFIANT Study of Left Ventricular Function and Exercise Performance after Acute Myocardial Infarction, 407
- Licitra G, *see* Di Pasquale, 875
- Lie K, *see* van Veldhuisen, 245
- Lijnen HR, *see* Verstraete, 801
- Lijnen P, van Hoof R, Amery A. Effects of Cilostazol vs. Nifedipine on Serum Lipoproteins in Patients with Mild to Moderate Hypertension, 509
- Lilleberg L, Sundberg S, Leikola-Pelto T, Nieminen M. Hemodynamic Effects of the Novel Cardiotonic Drug Simendan: Echocardiographic Assessment in Healthy Volunteers, 263
- Lipicky RJ, *see* Thadani, 611, 625
- Lirato C, *see* De Caprio, 735

- Liu P, Olivieri N. Iron Overload Cardiomyopathies: New Insights into an Old Disease, 101
- Liu Y, Cohen MV, Downey JM. Chelerythrine, a Highly Selective Protein Kinase C Inhibitor, Blocks the Anti-Infarct Effect of Ischemic Preconditioning in Rabbit Hearts, 881
- Lopez-Sendon J, de Sa E Lopez, Delcan JL. Ischemic Right Ventricular Dysfunction, 393
- Loufoua-Moundanga J, *see* Timour, 877
- McEntegart DJ, *see* Cowley, 829
- McKenna WJ, *see* Stewart, 95
- Maestri M, *see* Oneglia, 515
- Manzoli A, *see* Santarelli, 653
- Marin M, *see* Scognamiglio, 319
- Markianos M, *see* Kyriakides, 775
- Marabotti C, *see* Gistri, 169
- Marraccini P, *see* Camici, 221
- Masciocco G, *see* Modena, 153
- Mashiba H, *see* Hasegawa, 277
- Mattioli G, *see* Modena, 153
- Mellemagaard K, *see* Vaage-Nilsen, 147
- Melin JA, Wijns W, Vanoverschelde JL, Heyndrickx GR. Assessment of Left Ventricular Dysfunction by Nuclear Cardiology, 381
- Messerli FH. Antihypertensive Therapy: Past, Present, and Future, 7
- Messerli FH, *see* Beil, 425
- Messerli FH, Soria F. Ventricular Dysrhythmias, Left Ventricular Hypertrophy, and Sudden Death, 557
- Milan E, *see* Ferrari, 371
- Millar-Craig M, *see* Cowley, 829
- Miller MA, Texter M, Gmerek A, Robbins J, Shurzinske L, Canter D. Quinapril Hydrochloride Effects on Renal Function in Patients with Renal Dysfunction and Hypertension: A Drug-Withdrawal Study, 271
- Mitamura H, *see* Moritani, 749
- Miyabo S, *see* Fujiwara, 861
- Miyazaki T, *see* Moritani, 749
- Miyoshi S, *see* Moritani, 749
- Moalic J-M, *see* Besse, 581
- Modena MG, Masciocco G, Rossi R, Baraldi P, Mattioli G. Evaluation of the Effectiveness of Isradipine SRO in the Treatment of Hypertensive Patients with Left Ventricular Hypertrophy, 153
- Montresor G, *see* Arosio, 167
- Morris GK, *see* Cowley, 829
- Moritani K, Miyazaki T, Miyoshi S, Asanagi M, Zhao L-S, Mitamura H, Ogawa S. Blockade of ATP-Sensitive Potassium Channels by 5-Hydroxydecanoate Suppresses Monophasic Action Potential Shortening During Regional Myocardial Ischemia, 749
- Mulcahy D, *see* Purcell, 727
- Nakae I, Quan L, Hashimoto K, Sugimoto Y, Tsutamoto T, Kinoshita M. Mechanism of the Vasodilatory Action of Nicorandil on Coronary Circulation in Dogs, 137
- Nakai T, *see* Fujiwara R, 861
- Nakaoka T, *see* Kira, 251
- Natale A, *see* Santarelli, 653
- Naukkarinen V, *see* Thulin, 845
- Niaz MA, *see* Singh, 659
- Nicholls AJ, *see* Cowley, 829
- Nicholls DP, *see* Cowley, 829
- Nielsen I, *see* Vaage-Nilsen, 147
- Nieminen M, *see* Lilleberg, 263
- Nistri S, *see* Scognamiglio, 319
- Nordenström P, *see* Thulin, 845
- Oakley GDG, *see* Cowley, 829
- Ogawa S, *see* Moritani, 749
- Okabe F, *see* Kira, 251
- Olivieri N, *see* Liu, 101
- Omar S, *see* Timour, 877
- Oneglia C, Maestri M. Dysuria as a Side Effect of Dopamine Therapy, 515
- Opie LH, *see* Enous, 647
- Opie LH. Myocardial Stunning—Are Calcium Antagonists Useful? 533
- Opie LH, *see* Thadani, 719
- Opie LH. The Ever Expanding Spectrum of Ischemic Left Ventricular Dysfunction, 297
- Opie LH. The New Trials: AIRE, ISIS-4 and GISSI-3. Is the Dossier on ACE Inhibitors and Myocardial Infarction Now Complete? 469
- Orita H, Fukasawa M, Hirooka S, Fukui K, Kohi M, Washio M. In Vitro Protective Effects of Nicorandil on Hypothermic Injury to Immature Cardiac Myocytes: Comparison with Nitroglycerin, 129
- Orita H, Fukasawa M, Hirooka S, Uchino H, Fukui K, Washio M. In Vitro Evaluation of Phosphate, Bicarbonate and Hepes Buffered Storage Solutions on Hypothermic Injury to Immature Myocytes, 851
- Orito K, *see* Satoh, 227
- Palombo C, *see* Gistri, 169
- Pancera P, *see* Arosio, 167
- Paterno S, *see* Di Pasquale, 875
- Paulus WJ. Endothelial Control of Vascular and Myocardial Function In Heart Failure, 437
- Pauwels EJK, *see* van der Wall, 345
- Pedersen-Bjergaard O, *see* Vaage-Nilsen, 147
- Penner SB, Smyth DD. Central and Renal I_1 Imidazoline Preferring Receptors: Two Unique Sites Mediating Natriuresis in the Rat, 43
- Pfeffer MA, *see* Vaughan, 453
- Poole-Wilson PA, *see* Lewis, 407
- Pouleur H, Benedict CR, Rousseau MF. Neurohormones in Patients with Ischemic Left Ventricular Dysfunction, 313
- Pouleur H, *see* Hayashida, 741
- Priante F, *see* Arosio, 167
- Pritchard BNC. Clinical Experience with Moxonidine, 49
- Purcell H, Mulcahy D, Fox K. Nitrates in Silent Ischemia, 727
- Quan L, *see* Nakae, 137
- Rasmussen V, *see* Vaage-Nilsen, 147
- Ray S, Dargie H. Infarct-Related Heart Failure: The Choice of ACE Inhibitor Does Not Matter, 433
- Regan TJ, *see* Fabrizio, 89
- Remme W, *see* Venneker, 211
- Rengo F, *see* De Caprio, 735
- Ribul M, *see* Arosio, 167
- Robertson JIS. Dr. Robertson's reply to Dr. Kaplan, 675
- Robertson JIS. Guidelines for the Treatment of Hypertension: A Critical Review, 665
- Robbins J, *see* Miller, 271
- Rossi R, *see* Modena, 153
- Rousseau MF, *see* Hayashida, 741
- Rousseau MF, *see* Pouleur, 313
- Rüegg U, *see* Zierhut, 235
- Saida K, Umeda M, Itakura A. Improvement of Ischemic Myocardial Dysfunction by Nisoldipine, 365
- Salvadori P, *see* Camici, 221
- Salzmann R, *see* Zierhut, 235
- Santarelli P, Biscione F, Natale A, Manzoli A, Lanza GA. Electrophysiologic effects of Amlodipine vs. Diltiazem in Patients with Coronary Artery Disease and Beta-Blocking Therapy, 653
- Sasayama S. Effect of Coronary Collateral Circulation on Myocardial Ischemia and Ventricular Dysfunction, 327
- Sassen L, Lamers J, Verdouw P. Fish Oil and the Prevention and Regression of Atherosclerosis, 179
- Satoh K, Orito K, Yoneyama F, Taira N. A Further Study of the Vasodilator and Negative Inotropic Mechanisms of Action of Nicorandil and its Congeners in the Canine Heart, 227
- Schafer SG, *see* Ernsberger, 27
- Schmieder RE, *see* Beil, 425
- Scholten E, *see* van Veldhuizen, 245
- Scognamiglio R, Fasoli G, Nistri S, Marin M, Volta S Dalla. Left Ventricular Function and Prognosis after Myocardial Infarction: Rationale for Therapeutic Strategies, 319
- Sekine I, *see* Kira, 251
- Sestito M, *see* De Caprio, 735

- Sharma HS, Verdouw PD, Lamers JM. Involvement of the Sarcoplasmic Reticulum Calcium Pump in Myocardial Contractile Dysfunction: Comparison Between Chronic Pressure-overload and Stunning, 461
- Sheiban I, *see* Arosio, 167
- Shiraishi H, *see* Endo, 161
- Sjurzinske L, *see* Miller, 271
- Sigurd BM, *see* Vaage-Nilsen, 147
- Sillanpää J, *see* Thulin, 845
- Singh RB, Niaz MA, Ghosh S. Hypolipidemic and Antioxidant Effects of Commiphora Mukul as an Adjunct to Dietary Therapy in Patients with Hypercholesterolemia, 659
- Singh S, *see* Thadani, 199
- Smyth DD, *see* Penner, 43
- Sonneblick EH, *see* Fein, 65
- Sorace O, *see* Camici, 221
- Sørensen M Borring, *see* Vaage-Nilsen, 147
- Soria F, *see* Messerli, 557
- Sparrow J, *see* Holdright, 193
- Steiner J, *see* Holdright, 193
- Stewart JT, McKenna WJ. Management of Arrhythmias in Hypertrophic Cardiomyopathy, 95
- Storm C, *see* Venneker, 211
- Sugimoto Y, *see* Nakae, 137
- Sundberg S, *see* Lilleberg, 263
- Sung RJ. Low-Dose Amiodarone Should Not Be the First-line Treatment for Atrial Fibrillation, 773
- Swan HJC. Left Ventricular Dysfunction in Ischemic Heart Disease: Fundamental Importance of the Fibrous Matrix, 305
- Swanepoel CR. Which Diuretic to Use? 123
- Swynghedauw B, *see* Besse, 581
- Tabuenca MJ, *see* de Teresa, 837
- Taira N, *see* Satoh, 227
- Tanaka M, *see* Koga, 83
- Tauke J, Han D, Gheorghiade M. Reassessment of Digoxin and Other Low-Dose Positive Inotropes in the Treatment of Chronic Heart Failure, 761
- Texier M, *see* Miller, 271
- Thadani U, Lipicky RJ. Short- and Long-Acting Oral Nitrates for Stable Angina Pectoris, 611
- Thadani U, Chrysant S, Gorwit J, Giles T, Archer S, Iteld B, Singh S, Coppen D, Wakeford C, Hobbs S. Duration of Effects of Isradipine During Twice Daily Therapy in Angina Pectoris, 199
- Thadani U, Lipicky RJ. Ointments and Transdermal Nitroglycerin Patches for Stable Angina Pectoris, 625
- Thadani U, Opie LH. Nitrates for Unstable Angina, 719
- Thomas RD, *see* Cowley, 829
- Thulin T, Almkvist H, Berglund L, Björnsson T, Fagher B, Henningsen N, Honkavarma M, Naukkarinen V, Nordenström P, Sillanpää J, West K. Efficacy and Tolerability of Felodipine ER and Diltiazem SR as Monotherapy in Primary Hypertension: A Double-Blind Randomized Study, 845
- Timour Q, Aupetit J-F, Chevrel G, Loufoua-Moundanga J, Omar S, Faucon G. Time Course of Electrical Fibrillation Threshold During Brief Periods of Myocardial Ischemia and the Genesis of Fibrillation: Role of Calcium, 877
- Torfsgård KE, Ahlner J. Mechanisms of Action of Nitrates, 701
- Toshima H, *see* Koga, 83
- Tsiapras D, *see* Kyriakides, 775
- Tsutamoto T, *see* Nakae, 137
- Uchino H, *see* Orita, 851
- Umeda M, *see* Saida, 365
- Vaage-Nilsen M, Rasmussen, V, Hansen J Fischer, Hagerup L, Sørensen M Borring, Pedersen-Bjergaard O, Mellemgaard K, Holländer NH, Nielsen I, Sigurd BM. Effect of Verapamil on Arrhythmias and Heart Rate During 16 Months Following an Acute Myocardial Infarction, 147
- van der Wall EE, Cats V Manger, Chin JC, Pauwels EJK, Brusche AVG. Acute Effects of Intravenous Nisoldipine on Left Ventricular Function After Acute Myocardial Infarction, 345
- van Es PN, *see* Cosenzi, 473
- van Eyll C, *see* Hayashida, 741
- van Gilst W, *see* van Veldhuisen, 245
- Vanhaecke J, *see* Zmudka, 479
- van Hoof R, *see* Lijnen, 509
- van Hoogenhuyze D, *see* Venneker, 211
- Vanoverschelde JL, *see* Melin, 381
- van Schelven D, *see* Venneker, 211
- van Veldhuisen D, van Gilst W, de Smet B, de Graeff P, Scholtens E, Buijkema H, Girbes A, Wesseling H, Lie K. Neurohumoral and Hemodynamic Effects of Ibopamine in a Rat Model of Chronic Myocardial Infarction and Heart Failure, 245
- Van Zweiten PA, Chalmers JP. Different types of Centrally Acting Antihypertensives and Their Targets in the Central Nervous System, 787
- Vaughan DE, Pfeffer MA. Post-Myocardial Infarction Ventricular Remodeling: Animal and Human Studies, 453
- Venneker E, Remme W, van Hoogenhuyze D, Krauss XH, Bartels GL, Kruijsen D, Storm C, van Schelven D. Acute Systemic and Antiischemic Effects of Epanolol in Patients with Coronary Artery Disease, 211
- Verdouw P, *see* Sassen, 179
- Verdouw PD, *see* Sharma, 461
- Verstraete M, Lijnen HR. Novel Thrombolytic Agents, 801
- Vinolas X, *see* Bayes-de-Luna, 335
- Visioli O, *see* Ferrari, 371, 565
- Volta S Dalla, *see* Scognamiglio, 319
- Wakeford C, *see* Thadani, 199
- Waltman FL, *see* Cosenzi, 473
- Ward C, *see* Cowley, 829
- Washio M, *see* Orita, 129, 851
- Wesseling H, *see* van Veldhuisen, 245
- West K, *see* Thulin, 845
- Wijns W, *see* Melin, 381
- Wilson PA Poole. When to Start an ACE Inhibitor and in Whom, 111
- Wright C, *see* Holdright, 193
- Wynne RD, *see* Cowley, 829
- Yanagisawa M, *see* Endo, 161
- Yoneyama F, *see* Satoh, 227
- Zhao L-S, *see* Moritani, 749
- Zierhut W, Salzmann R, Bormann G, Rüegg U, Hof R. Pharmacological Actions of SDZ 218-135, a Novel Positive Inotropic Agent, 235
- Zmudka K, Dubiel J, Vanhaecke J, Flament W, de Geest H. Effects of Oral Pretreatment with Metoprolol on Left Ventricular Wall Motion, Infarct Size, Hemodynamics, and Regional Myocardial Blood Flow in Anesthetized Dogs During Thrombotic Coronary Artery Occlusion and Reperfusion, 479

Subject Index

Acadesine
biochemical and hematological effects, 195
effect on exercise-induced myocardial ischemia in chronic stable angina, 193–196
effect on rate-pressure product with exercise, 195
vs. nitroglycerine, 196
Acetabutol, with nifedipine, 572, 573
ACE inhibitors. *See* Angiotensin converting enzyme inhibitors
Acetaminophen, 724
Acetylcholine, 603, 606
blunted response, 439
vasodilatory response blunted in CHF patients, 77–78, 80
Action potential prolongation, SDZ 218–135 as positive inotropic agent, 235–243
Action potential shortening, blockade of IK.ATP by 5-hydroxydecanoate, 749–755
Acute Infarction Ramipril Efficacy study, 433, 434–435
ACE inhibitor trials, 469–471
ramipril effect on rate of reinfarction, 112, 113
significance, 435–436
use of ramipril and, 688
Acute myocardial infarction
before LV dysfunction, 373–374
DAVIT II verapamil trial on arrhythmias and heart rate, 147–151
endothelial dysfunction, 444
nisoldipine (IV) effects on LV function after, 345–350
Adenosine, as cardioprotective agent, acadesine as regulating agent, 193–196
Adenosine diphosphate, 708, 710
Adenosine regulating agents, acadesine, 193–196
Adenosine triphosphate (ATP), clonidine effect, 28
Adenosine triphosphate-sensitive potassium channels, blockade of IK.ATP by 5-hydroxydecanoate, 749–755
Adiastolic syndrome, 398
Adrenaline, 608
Adrenergic system, senescent heart overloading and failure, 581–585
Adrenergic vasoconstriction, α_1 receptors in Syndrome X, 221–225
Adrenomedullary chromaffin cells, 27, 28–29
Afterload, definition, 163
Afterload wall stress, to determine

afterload reduction for hydralazine administration, 161–166
Ageleponopsis aperta, 354
Aging
exogenous and endogenous coronary nitric oxide, 602
fibrous matrix function and collagen production, 311
senescent heart overloading and failure, 581–585
Agranulocytosis, vesnarinone side effect with congestive heart failure, 84
AIRE study. *See* Acute Infarction Ramipril Efficacy
Alcoholic cardiomyopathy, 89–93
clinical manifestation, 90
determinants of, 90
drug interactions, 93
preclinical stage, 89–90
therapy, 90–93
Alcohol restriction, hypertension and, 669
Aldosterone, 736
congestive heart failure, 687
vasodilators and dilated cardiomyopathy, 84
Alloxan, inducing diabetic cardiomyopathy in dogs, 67
Alpha-adrenergic blockade, hemodynamic response of dogs to hindquarter compression, 14–15
Alpha-adrenergic vasoconstriction, sympathetic overactivity, 15
 α_1 -adrenergic receptors, 36
 α_1 -adrenoceptor blocking drugs, vs. moxonidine, 49, 52–53, 54
 α_1 adrenoceptors, in Syndrome X, 221–225
 α_1 blockade, vs. moxonidine, 49, 52–53, 54
 α_2 -adrenergic receptors, imidazolines to produce side effects as well as lowering in blood pressure, 27, 29–30, 31, 33, 34–35, 36–37
 α_2 -adrenoceptors, stimulation in nucleus tractus solitarius (NTS), effect on arterial blood pressure, 21–26
Alpha-blocker, hypertension trials and, 668, 669
American Heart Association (AHA), 735 meeting in Atlanta, Nov. 1993, 720
American Society of Endocrinology, 736
Amiloride
decreasing reperfusion stunning, 536 for inhibition of interstitial myocardial fibrosis, 310
sensitivity as basis for subclassification of imidazoline preferring receptor subtypes, 43
with hydrochlorothiazide, 126
with loop diuretics, 126
p-aminoclonidine, 28
Amiodarone
for arrhythmia management in hypertrophic cardiomyopathy, 95, 98
in atrial fibrillation, 769–771
interaction with alcohol, for alcoholic cardiomyopathy, 93
low-dose not recommended as first-line treatment for atrial fibrillation, 773–774
not added to ACE inhibition for heart failure patients, 116
Amlodipine, 299, 724
electrophysiologic effects, 653–657
second generation, 356
vs. diltiazem, 653–657
vs. nifedipine, 657
vs. verapamil, 656, 657
Amrinone, in heart failure reassessment of, 764
Amrinone Multicenter Trial Group, 764
Anatomy of the heart, book review, 517
Aneurysmectomy, 117
Aneurysm formation, infarct expansion and, 455
Angina pectoris, 299
alcoholic cardiomyopathy presentation, 89
at rest, 719, 720
endothelin changes and myocardial ischemia, 589–596
isradipine duration of effects during twice daily therapy, 199–209
nicorandil as therapy, 144
nisoldipine in DEFIANT study, 408, 409, 410, 414
nitrate tolerance mechanisms, 489, 490, 491, 494
organic nitrate ester use, 701–702
transdermal nitrates for, 625–630
unstable, 719–724
Angiogenesis, heparin, potential to promote in canine and human models, 332–333
Angiotensin
aggravating pressure-induced tendency for cardiac hypertrophy, 17
endothelial damage, 444
Angiotensin I, endothelial control in heart failure, 437, 444
Angiotensin II, 603, 739
congestive heart failure and, 686, 687, 689

- endothelial control in heart failure, 437, 444
 escape from control of ACE inhibition, pathophysiologic role in LV dysfunction, 313–315
 hypertension treatment and, 669
 perindoprilat and the transient inward current in rabbit hearts, 647–650
 stimulus to vascular smooth muscle hypertrophy, 80
 vasodilators and dilated cardiomyopathy, 84
- Angiotensin converting enzyme, regression of LV hypertrophy with quinapril, 735–739
- Angiotensin converting enzyme inhibitors, 738, 739
 additions for heart failure management, 115–116
 additions for high risk post MI patient, 116–117
 AIRE, ISIS-4, and GISSI-3 trials, 469–471
 coronary artery disease and, 112
 duration of action, 434
 first dose hypotension, 434
 for alcoholic cardiomyopathy, 92, 93
 for dilated cardiomyopathy, 83, 84–85, 87
 for ischemic LV dysfunction, 313–315
 for prevention of heart failure, 112
 hypertension trials and, 668, 669
 in congestive heart failure asymptomatic patients, 80
 in congestive heart failure symptomatic patients, 79–80
 infarct-related heart failure, 433–436
 in heart failure, 111–112
 in heart failure, and neurohormonal mechanisms, 685–691
 initiation after myocardial infarction, 436
 LV dysfunction after myocardial infarction and prognosis, 319, 324
 mechanisms of action in congestive heart failure patients, 79
 modifying proliferation of fibrous matrix, 305, 310
 monotherapy to reduce LVH, 559
 nitrate tolerance, 496–497
 normalizing peripheral factors from congestive heart failure, 75, 79–80
 perindoprilat and the transient inward current in rabbit hearts, 647–650
 quinapril hydrochloride effects on renal function in hypertensive patients with renal dysfunction, 271–275
 role in postinfarct left ventricular dysfunction, better than nifedipine, 299, 300, 302
 sulphhydryl group, 433
 vs. moxonidine, 49, 52–54
 when to start and in whom, 111–113
 with diuretics, 126
- with simedan, 263
 Animal studies, fish oil effects on atherosclerosis and its risk factors, 179–188
- Anipamil
 second generation, 356
 vs. verapamil, 567
- ANOVA F test, isradipine studied in angina pectoris, 201–202
- Antabuse, for alcohol cardiomyopathy, questionable efficacy, 90
- Antiangiogenesis agents, isosorbide 5-mononitrate as, 693
- Antiarrhythmic drugs
 amiodarone not recommended as first-line treatment for atrial fibrillation, 773–774
 for dilated cardiomyopathy, 85
 with ACE inhibition for high risk post MI patient, 116
- Anticoagulants, with ACE inhibition for high risk post MI patients, 117
- Anticholinergic effect, disopyramide phosphate, for paroxysmal supraventricular tachycardia, 277
- Antihypertensives
 guidelines on initiation, 666, 667, 670
 history, development, and future trends, 7–9
 imidazoline I₁ receptors in the RVLM mediating blood pressure reduction, 21–26
 moxonidine as a selective I₁-imidazoline agonist, 27–38
- Antiischemics, epanolol treatment for coronary artery disease, 211–218
- Antioxidant, guggulipid decreasing of blood lipoproteins, 659–664
- Aortic input impedance, to determine afterload reduction for hydralazine administration, 161–166
- Arginine vasopressin
 congestive heart failure, contribution to, 76, 78
 heart failure and, 685, 686, 688
- Arrhythmias
 alcoholic cardiomyopathy, 89, 90
 interactions and risks after infarction, 335, 336, 337, 338, 339, 340
 left ventricular hypertrophy at risk factor, 16–17
 malignant, interactions and risks after infarction, 335, 341
 management in hypertrophic cardiomyopathy, 95–99
 perindoprilat and the transient inward current in rabbit hearts, 647–650
 prevalence before and after DAVIT I trial, 150
 prevalence before and after DAVIT II trial, 148–149, 150
 senescent heart overloading and failure, 581, 583, 585
- Arteriovenous fistula, cardiac hypertension, 308
- Aspirin
 after infarction for therapy, 113
 interaction with, 111–112
 interaction with alcohol, for alcoholic cardiomyopathy, 93
 unstable angina and, 719, 720, 721, 722, 724
 with ACE inhibition for high risk post MI patients, 117
- Asymptomatic Cardiac Ischemia Pilot Study (ACIP), 732
- Atenolol, 299
 vs. epanolol, 216
 vs. moxonidine, 49, 54, 57
- Atherosclerotic coronary artery disease, diabetic cardiomyopathy, 66
- Atherosclerosis, 11
 acceleration in patients with borderline hypertension, 15
 diet-induced, in monkeys, 180, 181, 183, 184
- diltiazem inhibitions induced by insulin, IGF-I, and PDGF in vascular smooth muscle cells, 861–869
- fish oil effect, and risk factors, 179–188
- guggulipids and, 659
- Athletes, cardiac hypertrophy, 308
- ATLAS study, lisinopril for heart failure, 112
- ATPase, 709, 710
- Atrial fibrillation
 alcoholic cardiomyopathy, 90, 92
 amiodarone not recommended as first-line treatment for atrial fibrillation, 773–774
- amiodarone therapy for, 769–771
 arrhythmia management in hypertension, 95–99
- LV hypertrophy as predictor and hypertension, 557
- Atrial natriuretic factor (ANF), heart failure and, 685, 686, 688
- Atrial natriuretic peptide (ANP) action mechanisms, 706, 709
- atria stretch and heart failure definition, 449, 451
- congestive heart failure role, 76
 heart failure and, 685, 686, 688
 neurohormones in LV dysfunction, 313–315
- Atrial pacing stress tests (APSI I and II), epanolol treatment for coronary artery disease, 211–218
- Atropine, effect on senescent heart, 584
- Australian National Health and Medical Research Council study, 426
- Autonomic nervous control, abnormalities in human hypertension, 11–18
- Autoregulation, J-curve in antihypertensive therapy, 757–759
- Backward failure theory, 448
- Balloon coronary occlusion, endothelial control in heart failure, 442, 723

- Baltimore study, senescent heart, 582
 Basic fibroblast growth factor (bFGF), intracoronary injection in canine heart leading to reduction in infarct size, 331, 333
 Basilen Blue, 706
 Bay-K-8644, 535–536, 567
 Bendrofluazide
 action after oral administration, 125
 for hypertension, with no glucose intolerance, 124
 Benzothiazepines, mode of action, limitations, efficacy and use, 565, 568, 569–573
 Beta-adrenergic agonists
 diabetic rats, diabetic cardiomyopathy, 68
 in heart failure, reassessment of, 763–764
 Beta-adrenoceptor blocking drugs, vs. moxonidine, 52–53, 54
 Beta-blockers
 adjuvant therapy (captopril, metoprolol, and their combination) for acute myocardial infarction, 875–876
 after infarction for therapy, 113
 amlodipine vs. diltiazem with coronary artery disease and beta-blocking therapy, 653–657
 bisoprolol effects on LV hypertrophy in essential hypertension, 837–842
 comments on Robertson's critical review, 673–674
 DEFIANT study of LV function and exercise performance after acute myocardial infarction, 414–415
 enalapril treatment for coronary artery disease, 211–218
 for diastolic heart failure, 111
 for dilated cardiomyopathy, 83, 87
 for ischemic LV dysfunction, benefits debated, 313, 315
 hypertension treatment and, 668, 669
 LV dysfunction after myocardial infarction and prognosis, 319, 323–324
 no improvement in prognosis with hypertrophic cardiomyopathy, 99
 plasma concentration of isosorbide dinitrate and, 697
 postinfarct management, 470–471
 silent ischemia, 727, 729, 731, 732
 unstable angina, 719, 720, 721, 722, 723, 724
 vs. moxonidine, 52–53, 54
 with ACE inhibition for high risk post MI patient, 116–117
 with aspirin for patients with myocardial infarction, 546–547
 with nitrates, 619–620
 BDF-6143, 32, 33
 abolishing central vasopressor action of moxonidine, 37
 Bethanidine, hypertension treatment guidelines, 668
 Bicarbonate buffer, evaluation of storage solutions on hypothermic injury to immature myocytes, 851–858
 Bisoprolol, effects on LV hypertrophy in essential hypertension, 837–842
 Blacks, salt sensitivity, 427
 Blindness, as result of hypertension, 7
 Blood flow, nicorandil analogue actions in canine heart, 227–233
 Blood pressure
 lowering effect on coronary vasodilator reserve in arterial hypertension, 169–170
 salt intake and cardiovascular structure, 425–430
 "Border" zones, 455
 Bovine, glyceryl trinitrate injections, 702, 704
 BQ-123, 596
 Bradyarrhythmias, beta-blockers for, 86
 Bradyarrhythmic syncope, hypertrophic cardiomyopathy and, 96
 Bradycardia, 400
 Bradykinin, 440, 441, 603, 607–608
 "Braking phenomenon" of diuretics, 123
 British Hypertension Society, 665, 666, 667, 668
 8-bromo-cGMP, 707, 709, 710, 711
 Bruce exercise test, 199
 β_1 selectivity, celiprolol vs. nifedipine, effect on plasma lipids, 509–513
 Buccal nitroglycerin, oral nitrates for stable angina pectoris, 611, 613, 619, 730
 Bucuculline, 37
 Bumetanide, action after oral administration, 125
 Butanol-1, 1, 3, 4-tetranitrate, 704
¹¹C-acetate, 386
 Calcitonin gene-related peptide, 603
 Calcium
 ischemic rise and reperfusion, 535
 role in intracellular functions, 353
 role in time course of electrical fibrillation threshold during myocardial ischemia and fibrillation, 877–878
 Calcium antagonists
 benefit or harm to consequences of coronary artery disease, 301
 cardioselectivity of, 353–362
 chemical structure of major families, 355
 contraindicated for patients with dilated cardiomyopathy, 84
 contraindicated in heart failure patients, 121
 differences in clinical practice, 565–573
 differences in potency between cardiac and vascular tissue, and within vessels, 356
 differential hemodynamic effects, 569–573
 first and second generation of, 356
 hypertension and, 668
 intracellular concentration, 709–710
 isradipine SRO to reverse left ventricular hypertrophy, 153–160
 myocardial stunning and calcium antagonist usefulness, 533–539
 prevention of postinfarct systolic left ventricular failure, 302–303
 silent ischemia and, 727, 729, 730, 731, 732
 tissue selectivity, 568–569
 tissue selectivity characterization, 354–358
 to prevent stunning before ischemia, 372
 to reduce LVH, 559
 vs. moxonidine, 52–53
 with ACE inhibitors for heart failure management, 116
 Ca²⁺ binding proteins, 465
 Calcium channel antagonist
 ischemia role in postinfarction heart failure, based on verapamil use in DAVIT II, 823–827
 isradipine duration of effects in angina pectoris, 199–209
 Calcium channel blockers
 blocking endothelin actions, 596
 diabetic cardiomyopathy role, 69
 diltiazem inhibitions induced by insulin, IGF-I, and PDGF in vascular smooth muscle cells, 861–869
 LV dysfunction after myocardial infarction and prognosis, 319–324
 neurohormones in LV dysfunction, 315
 nisoldipine DEFIANT study of LV function and exercise performance after acute myocardial infarction, 407–416
 no improvement in prognosis with hypertrophic cardiomyopathy, 99
 with nitrates, 619–620
 Calcium channel modulators, cardiac hypertrophy and response to, 358–359
 Calcium channels, classification of, 353–354
 Canadian Hypertension Society, 665, 668
 Ca²⁺ pump, performance of sarcoplasmic reticulum and ventricular failure, 461–467
 Calcium sensitizer, simendan effect, 263
 Calcium²⁺ transport, rats with diabetic cardiomyopathy, 68
 Calmodulin, 465
 Calsequestrin, 465
 CAMIAT study, amiodarone with ACE inhibitors for post MI patient, 116
 Capillary fluid shift, 503–504
 Captopril
 adjuvant therapy alone and with metoprolol for acute myocardial infarction, 875–876
 congestive heart failure treatment, 688, 689, 690, 691

- effect on glucose and lipid metabolism, 126
and flosequinan for chronic heart failure, 1 year comparative trial, 829–835
for congestive heart failure patients, 79, 80
for ischemic LV dysfunction, 313
hypotension risk reduction, 469, 470, 471
infarct-related heart failure, 433
in nitrate therapy, 493
megatrials of nitrates postinfarction, 644
mortality reduction with LV dysfunction after myocardial infarction, 324
nitrate tolerance, 504
preventing left ventricular enlargement, 456–458
SAVE study, 434–435, 458
vs. lisinopril, 434
vs. moxonidine, 53–54, 57
with ACE inhibitors for dilated cardiomyopathy, 84–85
with furosemide, 124
without potassium supplementation, 126
- Captopril Multicenter Research Group, ACE inhibition clinical efficacy for congestive heart failure patients, 79
- Carbochromen, 607
- Cardiac ACE, ibopamine in chronic myocardial infarction in rats, 245–250
- Cardiac Arrhythmia Suppression Trial (CAST)
antiarrhythmic drugs and dilated cardiomyopathy, 85
Class I antiarrhythmic drug therapy, 116
flecainide or encainide postinfarction therapy and higher mortality, 337
Cardiac death, with hypertrophic cardiomyopathy, 96–98
- Cardiac failure. *See* Heart failure
- Cardiac hypertrophy
mechanical load effect on protein synthesis in neonatal rat, 251–261
response to calcium channel modulators, 358–359
senescent heart overloading and failure, 581–585
- Cardiac myocyte
evaluation of phosphate, bicarbonate, and Hepes buffered storage solutions on hypothermic injury, 851–858
nicorandil protective effects on hypothermic injury, 129–134
nitroglycerin protective effects on hypothermic injury, 129–134
- Cardiac preservation, nicorandil vs. nitroglycerin effects on hypothermic injury to immature cardiac myocytes, 129–134
- Cardiac relaxation, SDZ 218–135 as positive inotropic agent, 235–243
- Cardiac transplantation
for alcoholic cardiomyopathy with end-stage heart disease, 93
iron overload cardiomyopathy, 108
stunning, 375
- Cardiogenetic shock
ischemic RV dysfunction, 401–402
nitrates in myocardial infarction, 640
- Cardiomyopathy
alcoholic, 89–93
diabetic, 65–70
iron overload, 101–109
- Cardioprotection, nisoldipine effect, 365–369
- Cardiovascular drugs, book review, handbook of contemporary drug therapy, 279
- Cardiovascular structure, salt intake and blood pressure effects, 425–430
- Cardioversion, amiodarone and atrial fibrillation, 769–771
- Cardioverter-defibrillator, implantable, evaluation being done for hypertrophic cardiomyopathy, 95, 98
- Carnitine
intervention for diabetic cardiomyopathy, 69
suggested for alcoholic cardiomyopathy, 92
- Carotid body, 28
- CAST study. *See* Cardiac Arrhythmia Suppression Trial
- Catecholamines, 36, 727
clonidine effect, 28, 29
- CD 349, second generation drug, 356
- Celiprolol, vs. nifedipine, effect on plasma lipids, 509–513
- Centrally acting antihypertensives, different types, and central nervous system targets, 787–797
- Central nervous system
autonomic nervous control abnormalities in human hypertension, 11–18
 I_1 receptor and imidazoline pharmacology, 21–26
nonspecific depression of function by stimulation of brain α_2 -adrenergic receptors, 27
organic nitrate esters and, 703
- Cerebrovascular damage, 8
- Cerebrovascular disease, 8
- cGMP-dependent protein kinase (cG-Pk), 707, 708, 709, 710
- Chelation therapy, to reverse iron overload in cardiomyopathy, 101, 102, 107–108
- Cheletrythrine, blocking antiinfarct effect of ischemic preconditioning in rabbit hearts, 881–882
- Chicken, atherosclerosis and fish oil effect on regression, 186–187
- Children, hydralazine for afterload reduction, ventricular septal defect, 161–166
- Chi-square test, 148
- Chlorthalidone, 125
action after oral administration, 125
reduction in LV mass, 559–560
salt restriction and left ventricular hypertrophy in therapy, 430
- Chlorthiazide
action after oral administration, 125
decreasing intracellular potassium and magnesium concentrations, 126
discovery, 7
diuresis and potency, 123
- Cholelithiasis, 206
- Cholesterol
Dr. Robertson's reply to Dr. Kaplan, 675
hypertension treatment guidelines critique, 665–670
- Choline, intervention for diabetic cardiomyopathy, 69
- Cholinergic receptor density, rats with diabetic cardiomyopathy, 68
- Chord method, 485
- Chromaffin cell membranes, 28–29, 32
- Chronic anemia, cardiac hypertrophy, 308
- Chronic heart failure
atrial natriuretic peptide responsiveness, 76
ibopamine neurohumoral and hemodynamic factors in rats, 245–250
- Chronic lung disease, with ventricular dysfunction, 382
- Cilazapril, for congestive heart failure patients, 79, 89
- Cimetidine, 28, 31–32, 36
- Cinnarizine, first generation drug, 356
- Cirazoline, 28
- Circadian, nitrates in silent ischemia, 727–732
- Cirrhosis
alcoholic cardiomyopathy, 89, 90
endothelin levels, 589
- Classification of calcium antagonists, cardioselectivity of, 353–362
- Clentiazem, second generation drug, 356
- Clinical trial, quinapril hydrochloride effects on renal function in hypertensive patients with renal dysfunction, 271–275
- Clonal neuron-like cell lines, 28
- Clonidine, 28–29, 31, 35, 36, 37–38
dose-dependent fall in mean blood pressure of SHR rats, 35
effect on indices of respiratory activity, 38
effect on mean atrial blood pressure, 21, 22, 23, 24, 25
high incidence of side effects, 27–28
hypertension treatment guidelines, 668
sedative effect, 49, 57
vs. moxonidine, 52–53, 54, 55–57
withdrawal side effects, 55

- Clonidine displacing substance (CDS), 21, 24, 25, 29
CMH test, 202
Cochran-Mantel-Haenszel (CMH) chi-squared test, isradipine studied in angina pectoris, 201
Collagens, 306
Collagen volume fraction, normal heart, 306
Collateral coronary flow, metoprolol, oral, and thrombolysis in acute infarction in dogs, 479-486
Combination therapy
 nitrate tolerance, 490, 496-497
 oral nitrates for stable angina, 619-620
Commiphora mukul, guggulipid decreasing of blood lipoproteins, 659-664
Comparative antihypertensive studies, moxonidine effect on blood pressure and systemic vascular resistance, 49, 52-57
Computed tomography scanning, to detect iron levels, 106
Conduction tissue disease, hypertrophic cardiomyopathy and, 98
Congestive heart failure (CHF), 8
 alcoholic cardiomyopathy, 90, 92, 93
 captopril decrease of furosemide effects, 124
 diabetic cardiomyopathy, 65, 66, 67
 endothelin control in heart failure, 439
 endothelin levels, 589, 591
 iron overload cardiomyopathy, 106
 neural and humoral adaptations to decreased cardiac output, 75-77
 nitrates in myocardial infarction, 640
 nitrate therapy, 501-505
 nitrate tolerance mechanisms, 489, 490, 491, 492, 496
 nuclear cardiology techniques for assessment, 381
 organic nitrate ester use, 701-702
 pathophysiology of, and dilated cardiomyopathy, 88
 peripheral consequences, 77-79
 peripheral factors in management of, 75-80
 plasma levels of atrial natriuretic peptide, 449, 451
 postinfarction ACE inhibitor therapy decrease in cardiac mortality, 335, 339
 post-myocardial infarction ventricular remodeling, 453-459
 quinaprilat therapy pharmacokinetic profile, 274
 as result of hypertension, 7
 simendan's hemodynamic effects in healthy volunteers studied by echocardiographic assessment, 263, 268
 therapy, 79
 use of neurohormonal and ACE inhibitors in, 685-691
CONSENSUS I and II. *See* Cooperative North Scandinavian Enalapril Survival Study I and II
Constrictive pericarditis, 400
Continuous versus intermittent treatment, transdermal nitrates for stable angina, 625-630
Contractile failure, in early myocardial ischemia: models and mechanisms, 818-820
Contractility
 alcoholic cardiomyopathy, 89-93
 cardiac myocytes treated with nicorandil or nitroglycerin, 130
 simendan effect in healthy volunteers, 263, 267-268
Cook County Heart Disease Registry, 553
Cooperative North Scandinavian Enalapril Survival Study I (CONSENSUS I), 314, 315
use of neurohormonal mechanisms and ACE inhibitors in heart failure, 686-687, 688, 689
Cooperative North Scandinavian Enalapril Survival Study II (CONSENSUS II), 433, 434-435, 436, 458
ACE inhibitors' use after infarction studied, 113, 685, 690
ACE inhibitor trials, 469-471
LV dysfunction after myocardial infarction and prognosis, 324
Cornell Medical Center, left ventricular hypertrophy, 427
Coronary angiography, 719
 alpha-1 receptors in Syndrome X, 221-225
 for dilated cardiomyopathy, 88
Coronary angioplasty, endothelin-1 levels during, 775-776
Coronary artery bypass graft (CABG) surgery, 729-730
Coronary artery diameter (CoD), nicorandil, nitroglycerin, and cromakalim vasodilatory action mechanism in dogs, 137-144
Coronary artery disease (CAD), 8, 719
 amlodipine vs. diltiazem electrophysiological effects, 658-657
 calcium antagonist differential hemodynamic effects, 569-573
 consequences, 301
 epanolog IV therapy, systemic and anti-ischemic effects, 211-218
 guggulipids in prevention of, 659, 663
 incidence, 7
 J-curve in antihypertensive therapy, 757-759
 left ventricular hypertrophy significance in cardiovascular morbidity and mortality, 549-554
 silent ischemia and, 727, 728, 729, 730, 731
Coronary artery spasm, before LV dysfunction, 373
Coronary blood flow (CBF), nicorandil's vasodilatory action mechanism in dogs, 137-144
Coronary Drug Project, 553
Coronary flow reserve, J-curve in antihypertensive therapy, 757-759
Coronary heart disease, sympathetic overactivity, 15, 18
Coronary reserve, alpha-1 receptors in syndrome X, 221-225
Coronary steal syndrome, 119, 566
Coronary thrombosis, sympathetic overactivity, 16
Coronary vascular bed, nicorandil analogue action in canine heart, 227-233
Coronary vascular resistance, epanolol in coronary artery disease, 213, 214-215, 216, 217
Coronary vasodilation, nisoldipine cardio-protective effect in rabbit hearts, 365-369
Coronary vasodilator, blood pressure lowering effect on reserve in arterial hypertension, 169-170
Corticosteroids, 604
Corynanthine, blocking clonidine antihypertensive action, 37
Cotton wool spots, 7
Counts method, 382
Cows, clonidine binding in bovine brain, 28, 29
¹⁴C-phenylalanine, incorporation rate, cultured myocardial cells and cyclic mechanical loading, 252-255, 256, 261
"Creep", 310
Cromakalim
 coronary effects with and without glibenclamide in dogs, 137, 138-142
 cytoprotection by nicorandil, 134
Cultured myocardial cells, mechanical load effect on protein synthesis in neonatal rats, 251-261
Cyclic mechanical load, effect on protein synthesis and morphological changes in cultured myocardial cells from neonatal rat, 251-261
Cyclic GMP, mechanisms of action of nitrates, 701-711
Cyclic nucleotides, 29
Cytochrome P-450, 701
 action mechanisms, 701, 705, 706, 710
 oxidase, 603-604
Danish Pilot Study, 543, 544
Danish Verapamil Infarction Trial I (DAVIT I), 543-547
Danish Verapamil Infarction Trial II (DAVIT-II), 147-151, 302-303, 408, 543-547, 823-827
DAVIT I and II. *See* Danish Verapamil Infarction Trial I and II
Death, ischemia role in postinfarction heart failure, based on verapamil use in DAVIT II, 823-827

- Debrisoquine, hypertension treatment guidelines, 668
- Deferoxamine, therapy for iron overload cardiomyopathy, 102, 107
- DEFIANT studies, 299
- LV function and exercise performance after acute myocardial infarction, 407-416
- DEFIANT I study, 408, 415-416
- limitations, 416
- DEFIANT II study, 407
- Delapril, for dilated cardiomyopathy, 84
- Denmark, fish oil effect on atherogenesis studied, 179-188
- Devereux's formula, 154
- Diabetes, adult-onset, 27
- Diabetes mellitus
- cardiomyopathy, 65-70
 - glucose intolerance and diuretic use, 124
- Diabetic cardiomyopathy, 65-70
- cardiac catheterization, 66
 - epidemiology, 65
 - experimental studies, 67-69
 - noninvasive studies, 66-67
 - pathology, 65-66
- Diabetic retinopathy, diabetic cardiomyopathy, 66, 67
- Diastole, 570
- senescent heart, 582
- Diastolic dysfunction
- acute ischemic syndrome, 297-303
 - alcoholic cardiomyopathy, 89-93
 - diabetic cardiomyopathy, 66, 67
 - iron overload cardiomyopathy, 101, 104-105, 106
 - nisoldipine effect on LV function and exercise performance after acute myocardial infarction, 407-416
- Diastolic function
- isradipine SRO effect on left ventricular hypertrophy, 155, 160
 - ranolazine with ischemic heart disease, 741-746
- Diastolic pressure index, 481, 484, 486
- Diastolic pressure time index, 484, 486
- Dichloracetate, intervention for diabetic cardiomyopathy, 69
- Diet
- guggulipid decreasing of blood lipoproteins, 659-664
 - use in hypercholesterolemia management, 659, 660, 661, 662
- Diethylamiloride, diminishing reperfusion arrhythmias, 536
- Digitalis, 377
- for alcoholic cardiomyopathy, 92, 93
 - to relieve congestive symptoms of dilated cardiomyopathy, 83-84, 85, 87
- Digitalis glycosides, in heart failure, reassessment of, 762-763
- Digoxin
- arrhythmogenic potentials in dilated cardiomyopathy patients, 83
- congestive heart failure treatment, 688
- effect on endothelial control in heart failure, 439
 - effect on left ventricular size and function, 458
- for hypertrophic cardiomyopathy, 98
- for ventricular septal defect, 161
 - in heart failure, 761-766
 - interaction with alcohol, for alcoholic cardiomyopathy, 93
 - therapy for congestive heart failure, 79
 - with ACE inhibitors for heart failure management, 115-116
 - with hydralazine and isosorbide dinitrate, 120
- Dihydropyridines, 354, 719, 724
- distribution pattern of receptors, 360, 361
 - for infarct related heart failure, 120
 - for ischemic LV dysfunction, 313
 - mode of action, limitations, efficacy and use, 565, 567, 568, 569-573
 - vascular selectivity of, 356-358
 - vs. moxonidine, 49, 52-53
- Dilated cardiomyopathy (DCM)
- alcoholism and, 89, 90
 - therapeutic management of, 83-87
- Diltiazem, 719, 724
- binding sites, 565, 566, 567, 568
 - cardiovascular ratio, 356
 - contraindicated for post myocardial infarction heart failure, 116
 - electrophysiologic effects, 653-657
 - first generation drug, 356
 - hemodynamic effects, 569-573
 - MDPIT study, 408
 - no inhibitory action, 357-358
 - preischemic effect on stunning or post-ischemic left ventricular mechanical dysfunction, 538
 - protective effect in experimental diabetic cardiomyopathy, 65, 69
 - reducing left ventricular mass, 554
 - vs. amlodipine, 653-657
 - vs. beta blockers in myocardial infarction, 547
- Diltiazem SR, efficacy and tolerability as monotherapy in hypertension, 845-848
- Dimaprit, 29, 36
- 1,2-dimethyl-3-hydroxypyrid-4-one (L1), for iron overload cardiomyopathy, 107, 108
- Dipyridamole, 607, 707
- vs. doxazosin, 224-225
 - with doxazosin treatment in Syndrome X, 221-225
- Dipyridamole test, 384
- Dipyridamole, action mechanisms, 703
- Disopyramide
- for hypertrophic cardiomyopathy, 98
 - interaction with alcohol for alcoholic cardiomyopathy, 93
- transient sexual dysfunction observed during antiarrhythmic therapy, 277
- Disulfiram, for alcoholic cardiomyopathy, questionable efficacy, 90
- Disuse atrophy, 300
- Diuretics
- choice of, 123-126
 - comments on Robertson's critical review, 673-674
 - congestive heart failure and, 686, 688
 - effect on median plasma norepinephrine levels in heart failure patients, 314
 - for correcting volume overload of alcoholic cardiomyopathy, 92, 93
 - for ventricular septal defect, 161
 - increasing ventricular ectopy, 561
 - LV dysfunction related to electrical instability, 337
 - nitrate tolerance, 496-497
 - no antiarrhythmic effect, 561
 - parenteral therapy, 125
 - postinfarct management, 471
 - predictor of neurohumoral activation, 456
 - tailored therapy for advanced heart failure, 85
- therapy for congestive heart failure, 79
- to reduce LVH, 559-560
 - to relieve congestive symptoms of dilated cardiomyopathy, 83-84, 87
 - as treatment of hypertensive, 668, 669
 - vs. moxonidine, 52-53, 54
 - with ACE inhibitors for heart failure, 111, 112, 115
 - with hydralazine and isosorbide dinitrate, 120
 - with verapamil in DAVIT-II study, 302
- DNA synthesis, inhibited by diltiazem in vascular smooth muscle cells, 861-869
- Dobutamine, ischemic right ventricular dysfunction, 393
- Dobutamine stress test, 384
- Docosahexaenoic acid, 179-188
- Docosapentaenoic acid, 179-188
- Dogs
- diabetic cardiomyopathy studies, 67
 - fish oil effect on atherogenesis in, 180, 186-187
 - hemodynamic response to hindquarter compression with/wo phenoxybenzamine, 14-15
 - metoprolol and thrombolysis in acute infarction, 479-486
 - nicorandil analogue action in canine heart, 227-233
 - nicorandil's vasodilatory action mechanism on coronary circulation, 137-144
- Dopamine
- dysuria as side effect, 515

- ischemic right ventricular dysfunction, 393
- Doppler Flow and Echocardiography in Functional Cardiac Insufficiency: Assessment of Nisoldipine Therapy. *See* DEFIANT study
- Doxazosin
- Syndrome X and adrenergically mediated coronary vasoconstriction, 221–225
 - vs. dipyridamole, 224–225
 - vs. nitrendipine, 473–476
- Doxorubicin, to inhibit calcium release from sarcoplasmic reticulum and lessen stunning, 536
- DPI 201-106
- chemical structure, 236
 - vs. SDZ 218-135, 235–236, 243
- Drug treatment, hypertension treatment guidelines critique, 665–670
- Drug withdrawal, quinapril hydrochloride effects on renal function in hypertensive patients, 273–274, 275
- Dunnett's test, nicorandil analogue action, 229
- Dylipoproteinemia, 8
- Dyslipidemia, 11, 15
- Dysuria, side effect of dopamine, 515
- Early afterdepolarizations, after infarction, risk factors, 336, 338
- ECHO evaluation, alcoholic cardiomyopathy, 93
- Echocardiography
- DEFIANT study of nisoldipine post-myocardial infarction, 409–410, 411–412, 414, 416
 - effect of blood pressure lowering on coronary vasodilator reserve in arterial hypertension, 169
 - nicardipine slow release modifications in peripheral hemodynamics and left ventricular function in hypertensives, 167–168
 - simendan hemodynamic effects in healthy volunteers, 263–268
 - to study isradipine SRO effectiveness in treating hypertension with left ventricular hypertrophy, 153–160
 - two-dimensional, to detect iron levels, 106
- Efaroxan, 24, 28, 33, 34–35, 36
- Efficacy
- felodipine ER and diltiazem SR as monotherapy for hypertension, 845–848
 - nitrates in silent ischemia, 727–732
- Effort angina
- acadesine effect, in chronic stable angina, 193–196
 - calcium antagonists for management of, 565–566
 - heparin effect on ventricular dysfunction, 327
- ischemic LV dysfunction, 297
- E-guggulsterone, 659, 663, 664
- Eicosapentaenoic acid, 179–188
- Ejection fraction
- after myocardial infarction, 320
 - fall resulting from treatment with vasodilators other than ACE inhibitors for infarct related heart failure, 119–121
- Elastin, 306
- Elderly
- ACE inhibitors in heart failure, 111
 - hyponatremia and thiazides, 125
 - quinapril therapy pharmacokinetic profile, 275
 - salt sensitivity, 427
 - senescent heart overloading and failure, 581–585
 - treatment of hypertension in, 666, 667, 669
- Electrical fibrillation threshold (EFT), 877–878
- Electrical instability, after myocardial infarction, risk stratification, 335–341
- Electrophysiology, amlodipine vs. diltiazem in patients with coronary artery disease and beta-blocking therapy, 653–657
- EMD 60263, 465
- EMIAT study, amiodarone with ACE inhibitors for post MI patient, 116
- EMPAT trial, 186
- Enalapril
- counteracted by aspirin, 117
 - for alcoholic cardiomyopathy, 92
 - for congestive heart failure patients, 79
 - for heart failure, 112
 - for heart failure in SOLVD study, 112
 - for ischemic LV dysfunction, 313–314, 315
 - hypotension risk, 469, 470
 - infarct-related heart failure, 433, 434–435
 - neurohormonal mechanisms and ACE inhibitors in heart failure, 685–691
 - nitrate tolerance, 504, 505
 - reduction of left ventricular end-diastolic volumes, 388
 - with ACE inhibitors for dilated cardiomyopathy, 84–85
- Encainide
- harmful to post MI patients given ACE inhibitors, 116
 - postinfarction therapy and higher mortality, 337
- Encephalopathy, hypertensive, 7
- Endocrin, 441
- Endocrin factors, 440–441
- Endocardium, role of, 437
- Endorphins, silent ischemia and, 728
- Endothelial cell muscarinic receptor defect, 439
- Endothelin, 601
- effect on myocardial contractility, 594
- endothelial control in heart failure, 437–444
- major effects on the heart: coronary tone, contractility, and electrophysiology, 592–594, 595
- myocardial ischemia and, 589–596
- Endothelin antagonists, 596
- Endothelin-I, levels during coronary angioplasty, 775–776
- Endothelium, dysfunction and acute myocardial infarction, 444
- endothelial dysfunction, 443–444
 - role of, 437
 - stimuli for release from cells, 439
- Endothelium-derived constricting factors, endothelial control in heart failure, 438, 439
- Endothelium-derived hyperpolarizing factor, 438
- Endothelium derived nitric oxide (EDNO), exogenous and endogenous coronary nitric oxide, 601–608
- Endothelium-derived relaxation factors (EDRF)
- endothelial control in heart failure, 438, 440–441
 - nitrates in congestive heart failure, 505
 - nitrates in myocardial infarction, 636
 - production impaired in congestive heart failure patients, 77–78, 80
- End-stage renal disease, as result of hypertension, 7
- End-stage heart disease, alcoholic cardiomyopathy and cardiac transplantation, 93
- End-systolic meridional wall stress (ESWS), 162–163
- Eosinophilia, beta-blocker induction of, in dilated cardiomyopathy, 84
- Enoximone, in heart failure, reassessment of, 765
- Enoximone Multicenter Trial Group, 765
- Epanolol
- systemic antiischemic effects in coronary artery disease, 211–218
 - vs. atenolol, 216
 - vs. pindolol, 216
- Epinephrine, 28, 29, 32, 33
- Epine, effect with ibopamine on PNE levels in rats with chronic myocardial infarction, 246–247, 248
- Equilibrium Binding Data Analysis (EBDA) program, 30
- Ergot alkaloids, 37
- Erythritol tetranitrate, 704
- Eskimos, fish oil and prevention and regression of atherosclerosis, 179–188
- Essential hypertension, 738
- doxazosin vs. nitrendipine as monotherapy, 473–476
 - evidence of increased adrenergic activity in early forms, 8

- therapy tailored to the individual patient, 8
- VA studies of antihypertensive treatment, 7
- Esterases, 701
- action mechanisms, 710
- Ethacrynic acid (ECA), 705, 706
- action after oral administration, 125
- Ethanol, 37
- chronic consumption and alcoholic cardiomyopathy, 89, 90, 93
- Etomoxir, intervention for diabetic cardiomyopathy, 69
- European Working Party on high blood pressure in the elderly (EWPH) trial, 669
- Exercise**
- ejection fraction with diabetic cardiomyopathy, 67
 - hypertension and, 669
 - inducing hypotension in hypertrophic cardiomyopathy patients, 97–98
 - isometric, response in patients recovering from myocardial infarction, 14, 15
 - isradipine duration of effects in angina pectoris, 199–209
 - monoxidine effect on renin angiotensin II, and aldosterone levels, 50
 - nitrate tolerance, 612, 614, 615–616, 617, 618
 - oral nitrates for stable angina, 611–620
 - residual ischemia and ventricular arrhythmia presence, 336–337, 338, 339
 - salt sensitivity, 429
 - senescent heart, 582–583
- Exercise capacity
- heparin effect on induced myocardial ischemia and ventricular dysfunction studied, 327–333
 - nitrates in congestive heart failure, 504–505
- Exercise-induced angina, before LV dysfunction, 373
- Exercise-induced ischemia
- adesine effect in chronic stable angina, 193–196
 - riboe effect, 195
- Exercise testing, DEFIANT-I study of LV function and exercise performance after acute myocardial infarction, 407, 410, 414, 416
- Exercise tolerance
- improved by vasodilators after infarct related heart failure, 119–121
 - iron overload cardiomyopathy, 102
- Exercise tolerance tests (ETT), isradipine in angina pectoris, 201–202, 203–205, 206–207, 208–209
- Exercise training, congestive heart failure therapy, 75, 80
- F-18 deoxyglucose activity, 385
- Falipamil, second generation drug, 356
- Fatty acids (n-3), effects on cell functions and blood constituents possibly involved in atherosclerosis, 181
- ¹⁸FDG, 387
- Felines, organic nitrate esters used in papillary muscles, 703
- Felodipine, 299
- second generation drug, 356
 - Felodipine ER, efficacy and tolerability as monotherapy in hypertension, 845–848
- Fenton reaction, 105
- Ferritin, role in iron overload cardiomyopathy, 104, 105, 106, 108
- Fibronectine, 306
- Fibrosis
- diabetic cardiomyopathy, 65, 66
 - senescent heart overloading and failure, 581, 583, 585
- Fibrous matrix
- proliferation modified by ACE inhibition, 305–311
 - schematic representation of organization, 307
 - synthesis of Type I collagen, LV dysfunction in ischemic heart disease, 305–311
- Fisher's exact test, 148
- two-sided, 202
- Fish oil
- effect on prevention and regression of atherosclerosis, 179–188
 - studies on effect of atherogenesis in the hypercholesterolemic rabbit, 180, 181–183, 185, 187
 - studies on effect on models of accelerated atherogenesis in pigs, 180–181, 183, 186–187
 - vessel graft atherogenesis, animal studies on fish oil effect, 185
- Flavin adenine dinucleotide (FAD), 603
- Flavin adenine mononucleotide (FMN), 603
- Flaxedil, 30
- Flecainide
- harmful to post MI patients given ACE inhibitors, 116
 - postinfarction therapy and higher mortality, 337
- Flosequinan
- and captopril for chronic heart failure, 1 year comparative trial, 829–835
 - Class III and Class IV heart failure, adverse effect, 120
 - with ACE inhibitors for heart failure management, 116
- Fluid volume homeostasis, salt intake effect, 426–427, 429–430
- Flunarizine, second generation drug, 356
- Forskolin, 536
- FORT trial, 186
- Forward failure, due to renal retention, 448
- FR139317, 596
- Fraction A of guggul, 663
- Framingham Cohort, left ventricular hypertrophy, 427
- Framingham study, 549, 550, 553
- diabetic cardiomyopathy incidence, 65, 66
 - sudden death incidence and myocardial infarction, 336
- Frank-Starling curve, 640
- Frank-Starling mechanism, 454
- senescent heart, 582
- Free radicals
- guggulipid's effect on, 663
 - relation with calcium overload, 536
 - stunning, 534
- Fructose, intervention for diabetic cardiomyopathy, 69
- Furosemide, ischemic RV dysfunction, 403
- Funnel-web spider toxin (FTX), 354
- Furosemide
- action after oral administration, 125
 - diuresis and potency, 123
 - intravenous treatment, 126
 - parenteral therapy, 125
 - with captopril, 124
 - with quinapril, 272
- Gallopamil, 299
- second generation drug, 356
 - vs. verapamil, 567
- Gas chromatographic method with electron capture detection (GC-ECD), measuring glyceryl trinitrates in plasma, 693–694
- Gas chromatography-mass spectrometry (GC-MS), measuring glyceryl trinitrates in plasma, 693–694
- Gated equilibrium imaging, 381–382
- Geometric method, 382
- GISSI-3 study, 644–645
- ACE inhibitor trials, 469–471
- Glibenclamide
- antagonist for nicorandil analogue action in canine heart and pK_B values, 227–233
 - blockade of IK_{ATP} by 5-hydroxydecanoate, 749–755
 - hemodynamic and coronary effects in dogs, 138
 - nicorandil analogue action in canine heart, 227–233
 - suppressing nicorandil effect on coronary blood flow, 137–144
- Global ischemia, nisoldipine cardioprotective effect in rabbit hearts, 365–369
- Glomerular filtration, diuretic use, 124
- Glomerular filtration rate (GFR)
- captopril effect on furosemide, 124
 - preservation and congestive heart failure, 76
- regression of LV hypertrophy with quinapril, 735–739

- Glucose intolerance, diuretic effects and conflicting reports on, 123, 124, 125, 126
- Glucose tolerance, impaired, 8
- Glutathione, 705
- Glutathione S-transferase (GST), 701, 705, 706, 710
- Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 465, 466
- 1,2-glycerol dinitrate (1,2-GDN) action mechanisms, 705, 706 chemical structure of, 702
- 1,3-glycerol dinitrate (1,3-GDN) action mechanisms, 705, 706 chemical structure of, 702
- Glyceryl dinitrates action mechanisms, 705 clinical pharmacokinetics of, 693–697
- Glyceryl mononitrites, 693–697
- Glyceryl trinitrate (GTN), *see also* Nitroglycerin chemical structure of, 702 clinical pharmacokinetics of, 693–697 mechanisms of action, 701–711
- Gpp(NH)p (guanine nucleotide regulatory protein), 32–33
- G-protein, 28–29
- Greenland, fish oil and the prevention and regression of atherosclerosis, 179–188
- Gregg phenomenon, 441
- Guanabenz, 23, 24, 27, 35
- Guanethidine discovery, 7 hypertension treatment guidelines, 668
- Guanafacine, 23, 24, 27, 35, 38
- Guanidines, 28
- Guanine nucleotide, 32
- Guanine nucleotide binding regulatory proteins (G proteins), 27
- Guanosine 5'-triphosphate, nitrate: action mechanisms, 706
- Guanylate cyclase, 706, 707, 708, 710, 711
- Guggulipid decreasing of blood lipoproteins, 659–664 diet study and, 661
- Guggulsterols, 663, 664
- Guggulsterones, 659, 663, 664
- Guglip, 660
- Guinea-pig, organic nitrate esters use in cardiac muscles, 703
- GUSTO study, streptokinase and hypertension risk, 469, 471
- Haber-Weiss reaction, 105
- [³H] clonidine, 28, 29–30, 36
- HDFP trial, 673
- Dr. Robertson's reply to Dr. Kaplan, 675
- Heart, endothelin and myocardial ischemia, 589–596
- Heart anatomy, book review, 517
- Heart attack, as result of hypertension, 7
- Heart failure ACE inhibitor choice, 433–436 additions to ACE inhibitors for post-infarct MI patients, 115–117 biochemical basis, 450–451 definition of, 447–451 digoxin and other low-dose positive inotropes reassessed, 761–766 endothelial control of vascular and myocardial function, 437–444 flosequinan and captopril 1 year comparative trial, 829–835 high output failure, 448 hypertension and, 450 iron overload cardiomyopathies, 101–109 ischemia role in postinfarction heart failure, based on verapamil use in DAVIT II, 823–827 neurohormonal mechanisms and ACE inhibitors, 685–691 neurohumoral influences, 448–449 sarcotubular Ca²⁺ pumps and ventricular failure, 461–467 senescent heart overloading and failure, 581–585
- Heart/liver transplantation, iron overload cardiomyopathy, 108
- Heart rate, verapamil effects on arrhythmias following acute myocardial infarction, 147–151
- Heart rate variability (HRV), 690
- Heart transplantation, maximum vasodilation in treatment of heart failure and DCM, 85–86, 87
- Heat shock proteins (HSPs), 465
- Hematocrit, high value as predictor of coronary mortality, 16
- Hemochromatosis definition, 101 iron overload cardiomyopathy, 101–109
- Hemodialysis, iron overload, 108
- Hemodynamics autonomic nervous control abnormalities in human hypertension, 14–18 calcium antagonist differential effects, 569–573 epanolol treatment for coronary artery disease, 211–218 hydralazine for afterload reduction in children with ventricular septal defect, 162, 163, 164 ibopamine in chronic myocardial infarction in rats, 245–250 isradipine in angina pectoris, exercise tolerance testing, 201–209 metoprolol, oral, and thrombolysis in acute infarction, 479, 480–486 moxonidine production of acute fall of blood pressure and systemic vascular resistance, 49, 51 moxonidine vs. nifedipine, 49
- nisoldipine (IV) after myocardial infarction, 347–349, 350 nitrates in congestive heart failure, 501–503 nitrates in myocardial infarction, 639, 640 peripheral factors in management, 75–80 right ventricular dysfunction, 397 SDZ 218–135 as positive inotropic agent in rabbit heart, 241–242, 243 SDZ 218–135 as positive inotropic agent in rat heart, 237, 239–240, 243 senescent heart, 582 simedan, cardiotonic drug with echocardiographic assessment, 263–268
- Hemorrhages, 7
- Hemosiderosis, definition, 101
- Heparin blocking endothelin actions, 596 for myocardial ischemia and ventricular dysfunction, 327–333 intravenous (IV) for unstable angina, 719, 720, 721, 722, 723, 724
- Heparin-Sepharose binding growth factor, 261
- Hepatic cirrhosis, not associated with alcoholic cardiomyopathy, 89, 90
- Heper buffer, evaluation of storage solutions on hypothermic injury to immature myocytes, 851–858
- Hibernating myocardium, *see also* Hibernation neurohormones in LV dysfunction, 315 ranolazine effect on LV regional diastolic function with ischemic heart disease, 741–746 zones, interaction between LV dysfunction and ischemia, 338
- Hibernation characteristics, 298 compared to stunning, 372 compensated mild ischemia with mechanical dysfunction, 300 ischemic right ventricular dysfunction, 396
- LV dysfunction after myocardial infarction and prognosis, 319–320, 322, 324 left ventricular dysfunction in patients, 371–377 vs. repetitive stunning vs. preconditioning, 300–301
- [³H] idazoxan, 28, 29
- High-density lipoprotein, 509, 510, 511–512, 513
- High density lipoprotein cholesterol (HDL) guggulipids and, 659 guggulipids decreasing of blood lipoproteins, 659–664
- Higher frequency (HF) rhythm, 690
- High risk hypertensives, J-curve in anti-hypertensive therapy, 757–759

- High-voltage activated (HVA) channels, 353–354
- Histamine, 29, 31, 36
- Histamine H₂ receptors, 36
- Histaminergic agents, 29
- [³H] moxonidine, 29–30, 31–33, 36
- Holiday heart syndrome, alcoholic cardiomyopathy, 90
- Holter monitoring
silent ischemia, 731, 732
- verapamil effect on arrhythmias and heart rate after acute myocardial infarction, 147–151
- Hope's backward failure theory, 450
- [³H]p-aminoclonidine, 30, 36
- HSP-27, 465, 466
- HSP-70, 466
- ³H-thymidine, incorporation rate, FCS effect in cultured myocardial cells, 253, 256, 261
- Hydralazine
discovery, 7
intervention for diabetic cardiomyopathy, 99
favorable hemodynamic effect on infarct related heart failure, 119–121
for ventricular septal defect in children, 161–166
hypertension treatment guidelines, 668
nitrates in congestive heart failure, 501
no effect on LV mass, 560
no attenuation of ventricular enlargement, 457
with isosorbide dinitrate for dilated cardiomyopathy, 85
with isosorbide dinitrate in congestive heart failure, 689
- Hydralazine/isosorbide dinitrate, combination use in congestive heart failure, 689
- Hydrochlorothiazide
action after oral administration, 125
effect on glucose and lipid metabolism, 126
high ceiling effect, 124
vs. furosemide, 124
vs. moxonidine, 49, 54, 55, 57
with amiloride, 126
with moxonidine, 54
- 5-Hydroxydecanoate, blockade of IK_AATP by, 749–755
- 6-Hydroxypyridine (6-OHDA), 38
- Hydroxyl, guggulsterone and, 663
- 5-Hydroxytryptamine (5-HT), 603
- Hyperalgesia, NO-cGMP and, 703
- Hypercholesterolemia
animal studies with, 181–184
guggulipids and, 659, 660, 663
interventions in dogs to develop atherosclerosis, 180, 186–187
vein graft atherogenesis, 185
with endothelial injury in pigs for atherosclerosis, 180–181, 183, 186–187
- Hyperemia, not normalized by phenolamine in CHF patients, 77, 79
- Hyperglycemia
control for prevention of diabetic cardiomyopathy, 65, 66, 69
diuretic use, 124
- Hyperinsulinemia, 11, 125
- Hyperkalemia, quinapril therapy and tolerance of, 275
- Hyperplasia, hypertrophy and, 307
- Hyper-reninemia, 8
- Hypertension
alcoholic cardiomyopathy, 90
associated with insulin resistance and diuretic use, 123
autonomic nervous control abnormalities, 11–18
bisoprolol effects on LV hypertrophy in essential hypertension, 837–842
blood pressure lowering effect on coronary vasodilator reserve, 169–170
book review, advances in hypertension research, experimental and clinical literature relating to blood pressure control and hypertensive disease, 279
cardiac hypertrophy and response to calcium channel modulators, 358–359
control for prevention of diabetic cardiomyopathy, 65, 66, 69
endothelin levels, 589
felodipine ER and diltiazem SR as monotherapy, a double-blind randomized study, 845–848
fibrous matrix function, 310–311
glomerular, quinapril hydrochloride effects on renal function in chronic renal failure patients, 271–275
heart failure and, 450
hyperkinetic borderline, 12, 15, 16, 17
insulin resistance and diuretics, 125
left ventricular hypertrophy presence, 557–561
moxonidine as a selective I₁-imidazoline agonist, 27–38
myocardial hypertrophy and, 427–430
myocardial hypertrophy and isradipine SRO effectiveness, 153–160
neurogenic borderline, 12
nicardipine slow release effect on peripheral hemodynamics and left ventricular function, 167–168
salt intake and, 425–427
therapy history, development, and future trends, 7–9
treatment guidelines critique, 665–670
white coat, 15
- Hypertensive heart disease, left ventricular hypertrophy presence, 557–561
- Hypertensive organ damage, 666
- Hypertrophy
adaptive process, sarcotubular Ca²⁺ pumps and ventricular failure, 462, 463–464, 467
- fibrous matrix function, 305, 306, 307–308, 310, 311
- Hyperuricemia, acadesine effect on exercise-induced myocardial ischemia, 196
- Hypertriglyceridemia, 125
- Hypertrophic cardiomyopathy (HCM), 95–99
accelerated AV conduction and accessory AV pathways, 96
arrhythmia management in, 95–99
conducting tissue disease, 96
treatment, 98–99
- Hypertrophy by ECHO, alcoholic cardiomyopathy, 93
- Hypokalemia, thiazide group of diuretics, 123, 124–125, 126
- Hyponatremia
congestive heart failure, correlation of blood levels, 76
thiazides in elderly, 125
- Hypotension, risk, and ACE inhibitors, 469–471
- Hypothermic injury
evaluation of phosphate, bicarbonate and Hepes buffered storage solutions for immature myocytes, 851–858
nicorandil vs. nitroglycerin protective effects to cardiac myocytes, 129–134
- Ibopamine
clinical pharmacokinetics of nitrates, 697
- neurohumoral and hemodynamic effects in chronic myocardial infarction in rats, 245–250
- plasma norepinephrine (PNE) level reduction in rats, 245, 246
- Idazoxan, 28, 36, 37
antagonist for clonidine ability to lower blood pressure, 43
blocking response to i.r. moxonidine in rats, 43, 45, 46, 47
effect on mean arterial blood pressure, 24
- I₁-Imidazoline agonists, moxonidine for hypertension control, 27–38
- I₁-Imidazoline receptors, 29, 36
- I₁-Imidazoline sites, 28–31, 33, 35, 36, 37
- I₂-Imidazoline sites, 28
- Imazodan, in heart failure, reassessment of, 765
- Imazodan Research Group, 765
- Imdur (60 mg), 720
- Imidazole binding sites, 28
- Imidazole-4-acetic acid (IAA), 36
- Imidazole receptors, 36
- Imidazoline binding sites, 24
- Imidazoline-guanadolinium receptive sites, 28
- Imidazoline preferring receptor, idazoxan blocking of response to i.r. moxonidine, 43, 45, 46–47

- Imidazoline receptors, centrally acting antihypertensive types, and central nervous system targets, 787–797
- Imidazolines, second-generation drug, effects as α_2 -adrenoceptor agonists, 21–26
- Imidazoline sites, 28
- Imidazoline receptor, moxonidine for hypertension control, 27–38
- Impotence, disopyramide side effect for antiarrhythmic therapy, 277
- Indapamide, action after oral administration, 125
- Indomethacin, inhibiting cyclooxygenase, endothelial control in heart failure, 441
- Inducible isoforms, 604
- Infarct expansion, 454–455
- Infarct related heart failure, treatment with vasodilators other than ACE inhibitors, 119–121
- Infarct size limitation, metoprolol and thrombolysis in acute infarction in dogs, 479, 480, 484, 486
- nitrates in myocardial infarction, 635–645
- Inositol phospholipid metabolism, 29
- Inotropes with ACE inhibitors for heart failure management, 116
- Inotropic agent, SDZ 218-135 pharmacological actions, 235–243
- Inotropic effects, nicorandil analogue action in canine heart, 227–233
- Insulin, 67, 69
- inducing diltiazem inhibition of DNA synthesis and Ca^{2+} uptake in vascular smooth muscle cells, 861–869
- Insulin resistance, 8
- beta-adrenergic stimulation, 15–16
- diuretic induced hypokalemia, 123, 124–125
- increased sympathetic tone and high insulin levels, 15–16
- Interleukin I, 437
- Intersalt Cooperative Research Group, 426
- Interstitial fibrosis, basis for increased ventricular stiffness in alcoholic cardiomyopathy, 89
- Intestinal fibrosis, 301
- Intoxication, alcoholic cardiomyopathy, 89, 90
- Intracoronary thrombolysis, coronary collaterals and ventricular function, 327–333
- Intravenous epanolol treatment for coronary artery disease, 211–218
- Intravenous nitroglycerin, nitrates in myocardial infarction, 635–645
- Intrinsic sympathomimetic activity (ISA), epanolol in coronary artery disease, 216–218
- [^{125}I]p-iodoclonidine ($[^{125}\text{I}]$ PIC), 29–30, 33, 34
- I_1 receptor, correlation between affinity for I_1 receptors and blood pressure lowering effects, 26
- Iron deposition, iron overload cardiomyopathy, 104
- effects on the heart, iron overload cardiomyopathy, 104–105
- kinetics, iron overload cardiomyopathy, 102–104
- overload cardiomyopathies, 101–109
- Iron-deficiency anemia, iron overload cardiomyopathy and, 103
- Iron overload cardiomyopathy, 101–109
- clinical presentation, 102
- definition, 101
- diagnosis, 105–106
- future directions of investigation, 108–109
- incidence, 101–102
- pathophysiology, 102–105
- predictors of prognosis, 106–107
- therapy, 107–108
- Ischemia. *See* Myocardial ischemia
- Ischemic cardiomyopathy, 301–302
- Ischemic contracture, nisoldipine cardio-protective effect in rabbit hearts, 365–369
- Ischemic heart disease
- fibrous matrix function, 305, 306, 308–309, 310
- organic nitrate ester and, 703
- ranolazine effect on LV regional diastolic function, 741–746
- Ischemic heart failure, isosorbide 5-mononitrate absorption rate and, 697
- Ischemic preconditioning, 465
- Ischemic right ventricular dysfunction, 393–404
- contributing factors, 401
- management of, 402
- mechanisms of, 396
- ISIS-4 trial, 644, 720
- ACE inhibitor trials, 469–471
- Isolated systolic hypertension, 667
- Isoproterenol, 535–536
- Isosorbide dinitrate (ISDN), 720, 723
- chemical structure of, 702
- clinical pharmacokinetics of, 693–697
- combination therapy with captopril, 496
- cross-tolerance with nitroglycerin, 490
- favorable hemodynamic effect on infarct related heart failure, 119–121
- long-acting nitrates, 643
- mechanisms of action, 701–711
- nitrates in congestive heart failure, 501, 504–505
- nitrate tolerance mechanisms, 489–497
- oral administration of, 696, 697
- oral nitrates for stable angina, 611, 613–616, 620
- silent ischemia, 730
- sublingual administration of, 696
- transdermal administration of, 696
- with hydralazine for dilated cardiomyopathy, 85
- with hydralazine in congestive heart failure, 689
- Isosorbide dinitrate cream, transdermal nitrates for stable angina, 625, 626
- Isosorbide 2-mononitrate (IS-2-MN), 693, 695, 696
- action mechanisms, 703
- chemical structure of, 702
- Isosorbide-5-mononitrate (IS-5-MN), 489–490, 644
- chemical structure of, 702
- clinical pharmacokinetics of, 693–697
- mechanisms of action, 701–711
- oral nitrates for stable angina, 611, 613, 616–619, 620
- silent ischemia, 730, 731, 732
- with atenolol and nifedipine, 620
- Isosorbide mononitrate, transdermal nitrates for stable angina, 628
- Isoverapamil, added after onset of reperfusion to lessen stunning, 537
- Iradipine
- binding affinities, 358
- binding parameters and functional parameters, 357
- cardiovascular ratio, 356–357
- developmental changes in rats, 359–360
- duration of effects during twice daily therapy in angina pectoris, 199–209
- second generation drug, 356
- vs. nifedipine, 200, 209
- vs. nisoldipine, 209
- Iradipine SRO, for myocardial hypertrophy as response to hypertension, 153–160
- J curve, in antihypertensive therapy, 757–759
- Kaplan's deadly quartet, 8
- K^+ channel, nicorandil's vasodilatory action mechanism on coronary circulation in dogs, 137–144
- K-channel opener, nicorandil analogue action in canine heart, 227–233
- Kidneys
- ACE-activity of ibopamine in chronic myocardial infarction in rats, 248–249
- atrial natriuretic peptide effect with congestive heart failure, 76
- moxonidine effect on rats and cows, 36
- mononidine effect on rat urine flow rate, 43–47
- quinapril hydrochloride effect on renal function in hypertensive patients with renal dysfunction, 271–275
- Korotkoff phase V, 736

- K-strophanthin, 377
 Kussmaul's sign, 400, 401
- L1, for iron overload cardiomyopathy, 107, 108
 Lacidipine
 lowering blood pressure, effect on coronary vasodilator reserve, 169–170
 second generation drug, 356
 LAD disease, 455
 Laminin, 306
 Laplace principle, 330
 LaPlace relationship, 455
 L-citrulline, 603
 L-cysteine, 705
 Left ventricular aneurysm, 397
 formation prevented by coronary collaterals, 327, 329–330
 wall motion abnormalities after infarction, 338, 341
 Left ventricular dilatation, LV dysfunction after myocardial infarction and prognosis, 324
 Left ventricular (LV) dysfunction, 686
 acute ischemic syndromes, 297–308
 after acute myocardial infarction and unstable angina, 373–374
 after angioplasty and resolution of coronary artery spasm, 373
 after exercise-induced angina, 373
 after open heart surgery, 374–375
 cardioselectivity and, 358–361
 due to hibernation in patients, 371–377
 due to ischemic heart disease, 377
 due to severe valvular disease, 377
 due to stunning in patients, 371–377
 interaction with ischemia after myocardial infarction, 335, 338, 339
 plasma neurohormone measurements, 313–315
 role of ACE inhibitors in, 691
 Left ventricular ejection fraction nisoldipine effects, 348, 349
 prognostic index of risk after infarction, 341
 Left ventricular enlargement
 clinical relationship with prognosis, 453, 454, 455
 prevention of, 456–459
 Left ventricular function
 after myocardial infarction and prognosis, 319–324
 interaction with electrical instability after myocardial infarction, 335, 337–338, 339, 341
 nicardipine slow release modifying in hypertensives, 167–168
 nisoldipine (IV) effects after acute myocardial infarction, 345–350
 nitrates in myocardial infarction, 640, 542
 Left ventricular hypertrophy (LVH), 8, 736, 738
 bisoprolol effects in essential hypertension, 837–842
 decreased with antihypertensive therapy, 7
 definition, 154
 diabetic cardiomyopathy, 65
 isradipine SRO for hypertension therapy, 153–160
 J-curve in antihypertensive therapy, 757–759
 reduction, and its effect on ventricular ectopy, 560–561
 regression, and implication for treatment, 554
 regression with quinapril, 735–739
 reversal with specific therapy, 559–560
 risk factor for sudden death, 557–561
 salt intake and morbidity, 427–430
 salt restriction, 430
 significance in cardiovascular morbidity and mortality, 549–554
 Left ventricular remodeling
 nisoldipine interaction favorable, 324
 prevention of, 456–459
 reversible LV dysfunction after myocardial infarction and prognosis, 320, 321
 vasodilator combination efficacy needing test trials after infarct related heart failure, 119–121
 Leu-enkephalin, clonidine effect, 28
 Leukocyte adhesion, 608
 LIGAND program, 30, 32
 Lipid metabolism, insulin resistance and diuretic induced hypokalemia, 123, 124, 125, 126
 Lipid peroxidation, 536
 Lisinopril
 for heart failure, 112
 megatrials of nitrates postinfarction, 644–645
 mortality risk decrease in GISSI-3 trial, 471
 vs. captopril, 434
 L-NMMA (N-monomethyl-L-arginine), 439, 441, 442, 602, 607
 vascular response in CHF patients, 77
 Loop diuretics, 123–124, 126
 action onset and duration after oral administration, 125
 Low cholesterol, increase in risk of non-cardiovascular events, 871–874
 Low-density lipoprotein (LDL), 509, 510, 511–512, 513
 NO-producing organic nitrate esters and, 703
 Low-density lipoprotein (LDL) cholesterol, guggulipid decreasing of blood lipoproteins, 659–664
 Low-dose infusion, nitroglycerin in myocardial infarction, 635, 638–639
 Low-frequency rhythm (LF), 690
 Lown's grading of ventricular arrhythmias, serial changes in DCM patients, 87
 Low output syndrome, ischemic RV dysfunction, 401–402
 Low-voltage activated (LVA) calcium channels, 354
 L-type calcium channels, 354
 structural model and subunits, 566, 567, 568
 Lupitidine, 29, 36
 McNemars test of symmetry, 148–149
 Macrophages, 604
 Magnesium
 suggested for alcoholic cardiomyopathy, 92
 with ACE inhibitors for heart failure management, 115
 Magnetic resonance (MR) imaging, to detect iron levels, 106, 108
 Malnutrition, alcoholic cardiomyopathy, 89, 90
 Management of Vasospastic Angina at Rest with Continuous Infusion of Isosorbide Dinitrate study, 721
 Manidipine, second generation drug, 356
 Mann-Whitney test, 148
 MDL 72567, second generation drug, 356
 MDPI study, 408
 Mean arterial pressure (MAP), 703
 Mechanical correction, 117
 Medical Research Council Working Party on Mild-to-Moderate Hypertension, 667, 669, 670
 Membrane proteins, senescent heart, 581–585
 Men
 alcoholic cardiomyopathy incidence, 90
 diabetic cardiomyopathy, 65
 Mepirodipine, second generation drug, 356
 Meta-analysis, hypertension treatment guidelines critique, 665–670
 Metabolic syndrome, 8
 autonomic nervous control abnormalities in human hypertension, 11–18
 Methapryraline, 36
 Methionine, 491, 493
 intervention for diabetic cardiomyopathy, 69
 Methylldopa
 α -methylldopa, 22, 23, 27, 35
 hypertension treatment guidelines, 668 with thiazides, 7
 α -methylnoradrenaline, 21, 22, 24
 α -methylnorepinephrine, 28, 35, 38
 Methyl palnoxirate, intervention for diabetic cardiomyopathy, 69
 α -methyl-p-tyrosine, 38
 Methysergide, 37
 Metaiodo benzylguanidine (MIBG) uptake, diabetic cardiomyopathy, 67
 Metoprolol, 729
 adjuvant therapy alone and with capto-

- pril for acute myocardial infarction, 875–876
for dilated cardiomyopathy, 84, 85–87
mortality reduction with LV dysfunction after myocardial infarction, 323–324
and thrombolysis, in acute infarction in dogs, 479–486
- Metoprolol in Dilated Cardiomyopathy (MDC) study**, 85, 87
- Metyrapone**, 706
- Mexiletine**, not useful with ACE inhibitors for post MI patients, 116
- Microangiopathy**, diabetic cardiomyopathy, 67
- Microvascular disease**, diabetic cardiomyopathy, 66
- Mild-to-moderate hypertension**, doxazosin vs. nitrendipine, 476
- Milrinone**
ambulatory treatment and increased mortality in heart failure patients, 337
in heart failure, reassessment of, 764–765
- Minnesota Living with Heart Failure Questionnaire**, 765
- Minoxidil**, no effect on LV mass, 560
- Mismatch metabolic pattern**, 300
- Molecular biology**, senescent heart overloading and failure, 581–585
- Monkeys**, fish oil effect on atherogenesis in, 180, 181, 183, 184, 186–187
- Monophasic action potential (MAP)**, 877–878
- Morbidity**
antihypertensive therapy by the stepped-care approach, 7
LV hypertrophy significance, 549–554
- Moricizine**, harmful to post MI patients given ACE inhibitors, 116
- Morphine analgesia**, 719, 721
- Morphological changes**, mechanical load effect in cultured myocardial cells from neonatal rat, 251–261
- Mortality**
antihypertensive therapy by the stepped-care approach, 7
LV hypertrophy significance, 549–554
nitrates in myocardial infarction, 635, 640–641, 644
- Moxonidine**
adverse side effects, 54–57
cardiac output, effect on, 50
centrally acting antihypertensive types and central nervous system targets, 787–797
dose-dependent fall in mean blood pressure of SHR rats, 35
effect on sodium excretion and urine flow rate in Sprague-Dawley rats, 43–47
fewer side effects, 8–9
hemodynamic studies, 49–57
- left ventricular hypertrophy, effect on, 51
most selective and potent known ligand for I_1 receptors, 21, 24, 26
pulmonary resistance, effect on, 51
sedative effect, 50
as selective I_1 -imidazoline agonist, 27–38
single dose effect, 52
systemic vascular resistance, effect on, 50
vs. ACE inhibitors, 49, 52–54
vs. α_1 -adrenoceptor blocking drugs, 49, 52–53, 54
vs. atenolol, 49, 54, 57
vs. beta-blockers, 52–53, 54
vs. calcium antagonists, 52–53
vs. captopril, 53–54, 57
vs. clonidine, 52–53, 54, 55–57
vs. diuretics, 52–53, 54
vs. hydrochlorothiazide, 49, 54, 55, 57
vs. nifedipine, 49, 51, 53, 55, 57
vs. prazosin, 54, 57
withdrawal side effects, 55
with hydrochlorothiazide, 54
- MRFIT trial**, 673
Dr. Robertson's reply to Dr. Kaplan, 675
meta-analysis of, 667
- Multicenter Diltiazem Post-Infarction Trial**, diltiazem effect on heart rate and supraventricular arrhythmias, 151
- Multiple-vessel disease**, neurohormones in LV dysfunction, 315
- Multivessel disease**, aneurysm rarely seen with extensive collaterals, 330
- Muscarinic receptors**, senescent heart overloading and failure, 581–585
- Myocardial blood flow**, coronary vasodilator reserve calculated by measurement of, 169–170
- Myocardial collagen**, fibrous matrix function in normal heart, in myocardial hypertrophy, and in myocardial ischemia and infarction, 305–311
- Myocardial function**, prognostic factor after acute myocardial infarction, 319
- Myocardial hypertrophy**, isradipine SRO for hypertensive, 153–160
- Myocardial infarction (MI)**
ACE inhibitors after, 436
adjuvant therapy (captopril, metoprolol, and their combination), 875–876
clinical risk factors and socioeconomic state factors, 335, 339
definition of heart failure, 451
endothelin and myocardial ischemia, 589–596
fibrous matrix function, 305, 306, 309–310
ibopamine neurohumoral and hemodynamic effects, 245–250
- LV dysfunction after, and prognosis for therapeutic strategies, 319–324
neurohormonal activation in, 690
nitrate therapy, 635–645
organic nitrate ester use, 701–702
patient response to isometric exercise, 14
perfused by collaterals, 327, 328–329
postinfarction ventricular remodeling, 453–459
risk stratification after, 335–341
verapamil trials, 543–547
- Myocardial ischemia**
acute ischemic syndromes, 297–303
after infarction, risk factors, 336
blockade of IK_{ATP} by 5-hydroxy-decanoate, 749–755
calcium antagonists before onset of, 537–538
calcium antagonists given during, 538
calcium rise and reperfusion, 535, 537
calcium role in time course of electrical fibrillation threshold, 877–878
characteristics, 298
chelerythrine blockage of antiinfarct effect of ischemic preconditioning in rabbit hearts, 881–882
clinical conditions subjecting heart to, 373
contractile failure in early myocardial ischemia: models and mechanisms, 813–820
endothelin levels and, 589–596
epanol treatment for reduction of, 211, 215–218
exercise-induced, acadesine effect in chronic stable angina, 193–196
fibrous matrix function, 305, 306, 308–309, 310
interactions with electrical instability, 336
interaction with electrical instability after myocardial infarction, risk stratification, 335–337
interaction with LV dysfunction, 338, 339
interaction with LV dysfunction after myocardial infarction, 335, 338
isradipine effects in angina pectoris, 199
left ventricular hypertrophy and hypertension linked to, 558
nisoldipine cardioprotective effect in rabbit hearts, 365–369
nitrates in, 727–732
nitrates in myocardial infarction, 639–640
possible mechanisms of delayed recovery, 298
role in collateral circulation and ventricular function, 327, 330–332
role in postinfarction heart failure, based on verapamil use in DAVIT II, 823–827

Myocardial oxygen extraction, epanolol in coronary artery disease, 213
 Myocardial rupture, infarct expansion and, 455
 Myocardial scar, 337
 Myocardium, contractile failure in early myocardial ischemia: models and mechanisms, 813–820
 Myocyte hypertrophy, 301
 Myocyte necrosis, ischemic right ventricular dysfunction, 396
 Myofibrils, mechanical load effect on protein synthesis in neonatal rat, 255, 258, 261
 Myoinositol, intervention for diabetic cardiomyopathy, 69
 Myosin, senescent heart overloading and failure, 581, 584
 Myosin heavy chain (MHC) mRNA, induced by mechanical stimulation in perfused beating hearts, 261

N-acetylcysteine (NAC), 708
 nitrate tolerance mechanisms, 491–498, 722
 with isosorbide dinitrate, 493
 NADPH, 603
 Naloxone, 37
 Naphazoline, 24, 28
 National Cholesterol Education Programme Adult Treatment Panel, 663
 Natriuresis, associated with antihypertensive effect of imidazoline preferring receptor agonists, 43, 44, 46
 Neovascularization, coronary collaterals as stimulus for, 330–332
 Nephropathy, diabetic cardiomyopathy, 66, 69
 Nephrosclerosis, 8
 N-ethylnicotinamide
 action as K-channel openers, 227
 weak vasodilator action, 232–233
 NETWORK, enalapril for heart failure, 112
 Neurohormonal mechanisms, ACE inhibitors in heart failure and, 685–691
 Neurohormones, in patients with ischemic left ventricular dysfunction, 313–315
 Neuropathy, diabetic cardiomyopathy, 66, 67
 Neuropeptide-Y, decrease during nitrate therapy, 504
 New York Heart Association heart failure (NYHA), class I
 SOLVD trial and, 688
 New York Heart Association class II alcoholic cardiomyopathy, 92
 SOLVD trial and, 688
 New York Heart Association class III alcoholic cardiomyopathy, 92
 SOLVD trial and, 688
 New York Heart Association class IV, 686

enalapril for alcoholic cardiomyopathy, 92
 NG 108-15 neuroblastoma-glioma cells, 28
 Nicardipine
 chronic stable angina, 299
 inotropic action, 567
 modifying peripheral hemodynamics and left ventricular function in hypertension, 167–168
 slow release, modifying peripheral hemodynamics and left ventricular function, 167–168
 Nicorandil
 analogue negative inotropic effects in canine heart, 229–230
 chemical structure, 228
 for angina pectoris, 144
 nicorandil analogue action in canine heart, 227–233
 vasodilatory action mechanism with and without glibenclamide on coronary circulation in dogs, 137–144
 vs. nitroglycerin protective effects on hypothermic injury to immature cardiac myocytes, 129–134
 Nifedipine
 added after onset of reperfusion to lessen stunning, 537
 binding parameters and functional parameters, 357
 binding site, 566
 cardiovascular ratio, 356–357
 coronary dilator activity, 568
 diastolic dysfunction, 299
 first generation drug, 356
 hemodynamic effects, 569–573
 hypertension treatment guidelines, 668
 inducing hypotension in LV remodeling, 324
 intrinsic negative effect, 572–573
 L-type calcium channel potency, 359
 no inhibitory action, 357–358
 not recommended for patients with post myocardial infarction heart failure, 116
 protective effect of calcium antagonists at onset of ischemia or hypoxia, 298
 silent ischemia and, 729, 730, 731
 SPRINT-I study, 408
 SPRINT-II study, 408
 TRENT study, 408
 unstable angina and, 719, 720, 721, 722, 723
 vs. celiprolol effect on plasma lipids, 509–513
 vs. isradipine, 200, 209
 vs. moxonidine, 49, 51, 53, 55, 57
 with acebutolol, 572, 573
 Nifedipine Retard, 509
 Niguldipine, second generation drug, 356
 Niludipine, second generation drug, 356
 Nimodipine, second generation drug, 356
 Nisoldipine

added after onset of reperfusion, 537, 538
 binding affinities, 358
 binding parameters and functional parameters, 357
 cardioprotective effect, 365–369
 cardiovascular ratio, 356–357
 coronary dilator activity, 568
 DEFIANT study of LV function and exercise performance after acute myocardial infarction, 407–416
 effects on LV function after acute myocardial infarction, 345–350
 hemodynamic effects, 347–349, 350
 increasing heart rate and decreasing LV systolic pressure generation, 300
 in DEFIANT study, 299, 302–303
 inhibitory action, 358
 lessening stunning, 536
 negative inotropic effect, 361–362
 plasma arginine vasopressin level changes, LV dysfunction patients, 313, 315
 reducing peripheral as well as coronary resistance, 324
 reflex sympathetic activation, 350
 second generation drug, 356
 tissue selectivity, 358
 unsuitable for use in acute phase of myocardial infarction, tachycardia risk, 350
 vs. isradipine, 209
 Nisoldipine-CC (Nisoldipine coat-core), 408, 409, 410, 411, 416
 DEFIANT I study, 408
 Nitrate dose escalation to override tolerance, nitrates for unstable angina, 719–724
 Nitrate receptors, 704
 Nitrates
 blocking endothelin actions, 596
 cardioprotection and myocardial infarction salvage, 636–638
 clinical pharmacokinetics of, 693–697
 for unstable angina, 719–724
 in congestive heart failure, 501–505
 in myocardial infarction, 635–645
 in silent ischemia, 727–732
 interaction with alcohol, for alcoholic cardiomyopathy, 93
 resistance, 639
 with beta-blockers, 619–620
 with calcium channel blockers, 619–620
 Nitrates in myocardial infarction, mega-trials of nitrates postinfarction, 644–645
 Nitrate tolerance, 613–616
 adverse effects of long-acting nitrates, 620
 biochemical (vascular) mechanisms of, 491–493
 combination therapy, 496–497
 endothelin and nitrovasodilators, role of, 601–608

- in congestive heart failure, 501–505
mechanisms of, 489–497
“neurohormonal activation” hypothesis, 495
nitrates for unstable angina, 719–724
physiological (systemic) mechanisms, 493–496
- Nitrendipine
inotropic action, 567
second generation drug, 356
vs. doxazosin, 473–476
- Nitric oxide (NO), 720
action mechanisms, 701, 703, 704–705, 706, 707, 709, 710
exogenous and endogenous coronary nitric oxide, 601–608
nitrates in myocardial infarction, 636
secreted by vascular endothelium, endothelial control in heart failure, 438, 442–444
- Nitric oxide (NO) synthase, 601–608
- Nitroglycerin, *see also* Glyceryl trinitrate
beneficial effects with limitation of infarct size, 457
coronary effects with and without glibenclamide in dogs, 187, 188–142
crosstolerance with isosorbide dinitrate, 490
intravenous (IV-NTG), clinical tolerance, 489–493, 496, 694, 695, 719–724
mechanisms of action of nitrates, 701–711
nitrates in congestive heart failure, 501, 502, 504
oral nitrates for stable angina, 611–620
oral administration of, 694
plasma concentration of, 697
sublingual and buccal administration, 694, 695, 722, 730, 731
sublingual, nitrates in myocardial infarction, 641–643
sublingual, nitrate tolerance, 491, 493
sustained-release, transdermal patches in therapy, 489, 494–495, 496
transdermal administration of, 694–695, 721, 723, 731, 732
transdermal, nitrates in myocardial infarction, 641–643
transdermal, oral nitrates for stable angina, 616, 617, 619, 620
treatment of infarct related heart failure, 119
vascular response in CHF patients, 77, 78, 80
vs. acadesine, 196
vs. nicorandil protective effects on hypothermic injury to immature myocytes, 129–134
with isradipine in angina pectoris study, 200, 201, 203, 205, 206
- Nitroglycerin ointment, transdermal ni-
- trates for stable angina, 625, 626, 721, 723
- Nitroglycerin patches, transdermal nitrates for stable angina, 625, 626–630
- Nitroprusside
endothelial control in heart failure, 442–443
favorable hemodynamic effect on infarct related heart failure, 119–121
nitrates in myocardial infarction, 641
tailored therapy for advanced heart failure, 85
ventricular arrhythmia prevalence diminished by, 558
- Nitrovasodilators, role of endothelium and, 601–608
- N-monomethyl-L-arginine (L-NMMA), 77, 439, 441, 442
- Noncardiovascular mortality, low serum cholesterol increase in risk of, 871–874
- Non-drug treatment, hypertension treatment guidelines critique, 665–670
- Nonsudden cardiac death, LV dysfunction after myocardial infarction and prognosis, 323
- Noradrenaline, 224, 603
- No-reflow phenomenon, nisoldipine cardioprotective effect in rabbit hearts, 369
- Norepinephrine, 28, 35, 68
causing plasma volume decrease, 16, 17
congestive heart failure, 687, 688, 690
organic nitrate esters and, 708
prognostic value in patients with LV dysfunction, 313–315
sympathetic release as peripheral factor in congestive heart failure, 75–76
- Normal heart, fibrous matrix function, 305, 306–307
- N-type Ca^{2+} channels, 354
- Nuclear medicine, LV dysfunction assessment, 381–389
- Nuclear resonance scattering (NRS)
from manganese-56, to detect iron levels, 106
- Nucleus tractus solitarii (NTS), 21, 22, 24, 28
- ω -conotoxin, blocking N channels, 354
- Omega-3 fatty acid, intervention for diabetic cardiomyopathy, 69
- One-vessel coronary artery disease, eptanol therapy, 211–218
- OPC-8212. *See* Vesnarinone
- Open heart surgery, before LV dysfunction, 374–375
- Oral inotropes, and digoxin, reassessment in treatment of chronic heart failure, 761–766
- Oral nitrates, in silent ischemia, 727–732
- Oral nitroglycerin, oral nitrates for stable angina, 611–620
- Organ damage, hypertension treatment guidelines critique, 665–670
- Organic nitrate ester ($\text{R}-\text{O}-\text{NO}_2$), 705
- Organic nitrates, tolerance mechanisms, 489–497
- Organic nitrate esters, mechanism of action, 701–711
- Osmolality, congestive heart failure correlation of blood levels, 76
- Overweight, 11, 15
- Oxymetazoline, 28, 31–32
- Pacemaker, conduction tissue disease and hypertrophic cardiomyopathy, 95, 98
- Papilledema, with retinopathy, 7
- Patient selection bias, 389
- PC12 cells, 28
- Pentaerythritol tetranitrate (PETN), 613, 619
mechanisms of action, 701
oral nitrates for stable angina, 611–620
- Percutaneous transluminal coronary angioplasty
before LV dysfunction, 373
chest pain and development of collateral circulation, 327
fish oil and restenosis in patients after, 185–188
ischemia giving rise to ventricular arrhythmias, 336
- Perindopril, 434
hypotension risk, 469
- Perindoprilat, and transient inward current in rabbit hearts, 647–650
- Periodic acid Schiff reactive deposits in hearts, diabetic cardiomyopathy, 69
- Peripheral hemodynamics, modified by nifedipine in hypertensives, 167–168
- Pertussis toxin, 28–29, 708
- Pharmacodynamics, moxonidine effect, 49–50
- Pharmacokinetics
moxonidine, summary of, 52
moxonidine vs. other antihypertensive drugs, 49–57
nitrates, clinical pharmacokinetics of, 693–697
- Phenoxybenzamines, 28, 31, 32, 37
hemodynamic response in dogs to hindquarter compression, 14–15
- Phentolamine, 28, 36
alpha-1 receptors in Syndrome X, 224, 225
not normalizing hyperemia in congestive heart failure patients, 77
- Phenylalkylamines, mode of action, limitations, efficacy and use, 565, 567, 568, 569–573
- Phenylephrine, 28, 31–32
endothelial damage, 444

- Phenylethanolamine-N-methyltransferase, 29
- Phenylethylamine, 32
- Phenytoin
interaction with alcohol, for alcoholic cardiomyopathy, 93
not useful with ACE inhibitors for post MI patients, 116
- Phlebotomy, for iron overload cardiomyopathy, 108
- Phosphate buffer, evaluation of storage solutions on hypothermic injury to immature myocytes, 851–858
- Phosphatidylinositol (PI) cycle, 180
- Phosphodiesterase (PDE) inhibitors for congestive heart failure management, 84
in heart failure, 764–765
inhibition slight for SDZ 218-135 as positive inotropic agent, 239
producing unacceptable side effects in chronic heart failure patients, 84
- Phospholamban, 462, 463, 465, 466, 709
- Physical deconditioning, congestive heart failure, consequences of adaptations, 75, 78–79
- Pigs, fish oil effect on atherogenesis in, 180–181, 183, 186–187
- Pimobendan, in heart failure, reassessment of, 765
- Pimobendan Multicenter Study Group, 765
- Pindolol, 723
vs. epanolol, 216
- Piperazines, ranolazine, 741–746
- Piperoxan, 37
- Piretanide, for dilated cardiomyopathy, 84
- Plasma catecholamines, elevation in young subjects with mild hypertension, 11
- Plasma concentrations
clinical pharmacokinetics of nitrates, 693–697
- isradipine in angina pectoris, 201, 202, 205, 206
- norepinephrine, 685, 686, 687, 689, 690
- renin activity (PRA), 669, 686, 687, 688
- Plasma lecithin cholesterol acyltransferase activity (LCAT), 509, 510, 512
- Plasma lipids, celiprolol vs. nifedipine effects, 509–513
- Plasma neurohormones, ibopamine in chronic myocardial infarction in rats, 245–250
- Plasma norepinephrine (PNE), reduction by ibopamine in rats with chronic myocardial infarction, 244–250
- Plasminogen activators, thrombolytic agents, 801–809
- Platelet activating factor, 601, 603
- Platelet-derived growth factor, inducing diltiazem inhibitions in vascular smooth muscle cells, 861–869
- Polyunsaturated (n-3) fatty acids, fish oil and prevention and regression of atherosclerosis, 179–188
- Polyvalent antagonists, cardioselectivity of calcium antagonists, 353
- Positron emission tomography, 387, 727
alpha-1 receptors in Syndrome X, 221–225
imaging, LV dysfunction, 385–387
- Post-extrasystolic potentiation (PESP), regional myocardial dysfunction changes induced by, 321, 322–323
- Post-infarction
ACE inhibitors and ventricular enlargement, 112–113
DEFIANT study of LV function and exercise performance, 407–416
fibrous matrix function, 305, 306, 309–311
- Postinfarction angina, coronary collaterals and ventricular function, 328
- Post-infarction arrhythmias, verapamil effect studied in DAVIT II trial, 147–151
- Post-infarction remodeling, fibrous matrix function, 305, 306, 309–311
- Postinfarct left ventricular dysfunction, 299
- Post-myocardial infarction, additions to ACE inhibitors, 115–117
- Potassium
contractile failure in early myocardial ischemia: models and mechanisms, 813–820
with ACE inhibitors for heart failure management, 115
- Potassium-channel opener, nicorandil analogue action in canine heart, 227–233
- Potassium channels (K^+)
charybdotoxin sensitive (ChTx), 704
nicorandil's vasodilatory action mechanism on coronary circulation in dogs, 137–144
- Potassium channels (K_{ATP}), contractile failure in early myocardial ischemia: models and mechanisms, 813–820
- Prazosin, 37
effect on myocardial remodeling, 121
pretreatment attenuation of response to i.c.v. moxonidine, 43, 44–45, 47
vs. moxonidine, 54, 57
- Preconditioning, 300–301
characteristics, 298
- Prinzmetal's angina, 336, 719, 720
before LV dysfunction, 373
calcium antagonists for effective therapy, 565
- Primary hemochromatosis, iron overload cardiomyopathy, 102, 106
- Probucol, 663
- Procainamide, interaction with alcohol for alcoholic cardiomyopathy, 93
- Procollagen III, 306
- Prodrugs, organic nitrate esters as, 704
- Prognosis
additions to ACE inhibitors for post MI patients, 115–117
- LV dysfunction after myocardial infarction, rationale for therapeutic strategies, 319–324
- Progression, atherosclerosis, fish oil effect, 179–188
- Progressive heart failure cycle, 686
- Promethazine, 29
- Propafenone, for hypertrophic cardiomyopathy, 98
- Propranolol, 37
causing plasma volume decrease, 16
effect on senescent heart, 584
mortality reduction with LV dysfunction after myocardial infarction, 323–324
pretreatment for SDZ 218-135 in rat hearts, inotropic action studied, 240–241
- Prospective Randomized Milrinone Survival Evaluation trial (PROMISE), 764–765
- Prostacyclin, 601, 603
- Prostaglandin synthesis, 704
- Protein kinase C, 710, 881–882
- Protein synthesis, mechanical load effect and morphological changes in cultured myocardial cells from neonatal rats, 251–261
- Proteinuria, 7
- Proto-oncogenes, 465
- Pro-urokinase, thrombolytic agents, 801–809
- Prudent diet, guggulipid decreasing of blood lipoproteins, 659–664
- Pseudotolerance, 606
- Pulmonary edema, 7
nitrates in congestive heart failure, 504–505
- Quality of life
trade-off for increase in life expectancy, 7
vasodilators for infarct related heart failure, 119–120
- Quinapril, 690
dosage, 275
quinapril hydrochloride effects on renal function in hypertensive patients with renal dysfunction, 271–275
regression of LV hypertrophy, 735–739
with furosemide, 272
- Rabbits
chelerythrine blockage of antiinfarct effect of ischemic preconditioning, 881–882
- fish oil studies related to atherogenesis, 180, 181–183, 185, 187
moxonidine presynaptic action, 38

- nisoldipine cardioprotective effect, 365–369
 SDZ 218–235 as positive inotropic agent in rabbit heart, 237–238, 241–242, 243
 Racemic threitol tetrinitrate, 704
 Radioisotopes, thallium imaging to assess left ventricular dysfunction, 381–389
 Radionuclide angiography measurements before and after IV nisoldipine to check LV function after infarction, 345, 346
 to study iron overloads, 106
 Radionuclide ventriculography, 382 to detect iron levels, 106
 Ramipril, 433, 435
 congestive heart failure treatment, 688 postinfarct management, trials, 470, 471
 Random efficient regression (RCG) model, 202
 Ranitidine, 29, 36
 Ranolazine, effect on LV regional diastolic function with ischemic heart disease, 741–746
 Rate-pressure double product, isradipine therapy effect, 199, 207–208
 Rate-pressure product epanol in coronary artery disease, 214, 215, 216, 217
 nisoldipine (IV) effects after infarction, 347, 348, 350
 Rats brain binding sites of imidazoline receptors, 28, 37
 central and renal I_1 imidazoline preferring receptors, 43–47
 clonidine displacing substance injection in C_1 area of RVLM, blood pressure reduction, 24, 25
 diabetic cardiomyopathy, 68, 69
 fish oil animal studies of atherogenesis, 185
 glyceryl trinitrate injections, 702, 703, 704
 ibopamine in chronic myocardial infarction studied, 245–250
 mechanical load effect on protein synthesis in neonatal rats, 251–261
 moxonidine's ability to normalize hypertension by an action within RVLM, 27, 29, 30, 33, 34
 neurogenic component in pathophysiology found, 12
 SDZ 218–235 pharmacological actions as positive inotropic agent, 235–243
 Rauwolfia, 22, 668
 Rauwolscine, 35, 37
 ^{87}Rb images, 387
 Reaven's syndrome, 8
 Rebound phenomenon, 23, 727–732
 Receptor dependent and independent NO release, endothelium and nitrova-
- sodilators, role of, 601–608
 Recombinant tissue-type plasminogen activator (rt-PA), 458
 Referred care, 675
 Regional left ventricular function, metoprolol and thrombolysis in acute infarction in dogs, 479–486
 Regional myocardial ischemia, blockade of IK-ATP by 5-hydroxydecanoate, 749–755
 Regional wall motion, ranolazine effect on LV regional diastolic function with ischemic heart disease, 741–746
 Regional wall motion index, nisoldipine, 348–349
 Regression, atherosclerosis, fish oil effect, 179, 185–187, 188
 Reinfection, ischemic role in postinfarction heart failure, based on verapamil use in DAVIT II, 823–827
 Relaxation, senescent heart overloading and failure, 581–585
 Remodeling, 113
 developmental changes in rats, 359–361
 nitrates in myocardial infarction, 637, 640
 postinfarction ventricular remodeling, 453–459
 vasodilators other than ACE inhibitors for infarct related heart failure, 119–121
 Renal disease, hypertensive, 27
 Renal failure, 8
 endothelin levels, 589
 incidence, 7
 quinapril hydrochloride effects on renal function in hypertensive patients, 271–275
 Renal impairment, 8
 quinapril hydrochloride effects in hypertensive patients with renal dysfunction, 271–275
 Renin-angiotensin-aldosterone system (RAS), 739
 activation in senescent heart, 585
 congestive heart failure and, 685, 686, 690
 neurohormonal mechanisms and ACE inhibitors in heart failure, 685–691
 neurohumoral activation, 456
 neurohumoral influences of heart failure, 448–449, 450, 451
 nitrate tolerance, 493, 495
 role in development of LVH, 558
 salt intake effect, 429–430
 Reperfusion as adjunctive therapy with nitrates in myocardial infarction, 641
 calcium antagonists added after the onset of, 537, 538
 calcium antagonists at time of, 536–537
 endothelial level reduction and myocardial ischemia, 589–596
 increased cytosolic calcium mechanism, 534–536
 injury definitions, 534
 metoprolol and thrombolysis in acute infarction in dogs, 479–486
 spectrum of injury, 533–534
 Reperfusion arrhythmias, SDZ 218–235 as positive inotropic agent, 235–243
 Reserpine, 22, 38
 discovery, 7
 with thiazides, 7
 Resistance vessels, nicorandil analogue action in canine heart, 227–233
 Restenosis
 atherosclerosis, fish oil effect, 185–186
 fish oil efficacy in prevention, after percutaneous transluminal angioplasty, 179–188
 "Resting state", 568
 Retinopathy
 diabetic cardiomyopathy, 66, 67, 69
 with papilledema, 7
 Revascularization, in post MI heart failure patients, 117
 Reversible dysfunction, 383–384
 Reversible myocardium contractile dysfunction, 319
 Rheumatic valve disease, 450
 Ribose, effect on exercise-induced ischemia, 195
 Right atrial pressure (RAP), ischemic right ventricular dysfunction, 397–398, 399, 400, 401, 402
 Right heart failure, pathophysiology, 393–394
 Right ventricular aneurysm, 397
 Right ventricular infarction, predisposing factors and incidence of, 394–395, 397, 400, 401
 Right ventricular ischemia, 395–396
 Rilmenidine, 21, 24, 37, 38
 blocked by an imidazoline-specific antagonist, 43
 centrally acting antihypertensive types, and central nervous system targets, 787–797
 dose-dependent fall in mean blood pressure of SHR rats, 35
 as I_1 -selective antihypertensive, 27, 28, 29, 33, 35, 36
 Risk stratification
 after myocardial infarction, 335–341
 changes in thrombolytic era, 340–341
 multifactorial approach, 340
 RO-5967, second generation drug, 356
 Rostral ventrolateral medulla oblongata (RVLM), 38
 site of imidazolines stimulating I_1 -imidazoline receptors to lower blood pressure, 27–33, 36
 sympathetic activity attenuated and

- regulation of blood pressure, 21, 24, 25–26
- Royal Brompton National Heart and Lung Hospital, 194
- Ruthenium red, 464
- Ryanodine, 464, 536, 584–585
to reduce systolic contraction in rats, 359–361
- 8663S, second generation drug, 356
- Salt intake, as determinant of left ventricular hypertrophy, 428–430
- Salt restriction, left ventricular hypertrophy, 430
- Salt sensitivity, 427
- Sarcoplasmic reticulum, Ca^{2+} pumps and ventricular failure, 461–467
- SAVE study. *See* Survival and Ventricular Enlargement (SAVE) study
- Scleroderma, endothelin levels, 589
- scu-PA, thrombolytic agents, 801–809
- SDZ 218–135
chemical structure, 236
positive inotropic agent pharmacological actions, 235–243
vs. DPI 201–106, 235–236, 243
- Secondary hemochromatosis, iron overload cardiomyopathy, 102, 106, 107
- Secondary prevention, beta-blockers and aspirin for patients with myocardial infarction, 546–547
- Selozok, 479, 481
- Senescence
heart overload and failure, 581–585
molecular data of heart, 583–585
physiological data of senescent heart, 582
- SERCA 2 gene, 464
- SERCA 2 isoform, 464
- Serotonergic pathways, centrally acting antihypertensive types, and central nervous system targets, 787–797
- Serum cholesterol, hypertension and, 669–670
- Sestamibi imaging, 389
99m-Tc-Sestamibi imaging, 385
- Sexual dysfunction, disopyramide therapy side effect, 277
- SG-86,
chemical structure, 228
nicorandil analogue action in canine heart, 227–233
- SG-103
chemical structure, 228
nicorandil analogue action in canine heart, 227–233
- SG-209
chemical structure, 228
nicorandil analogue action in canine heart, 227–233
- SHEP trial, 667
- Sickle cell anemia, iron overload cardiomyopathy and, 102
- Silent myocardial ischemia
nitrates in, 727–732
prognostic factor after acute myocardial infarction, 319, 320–323, 324
- Simendan
adverse events in healthy volunteers, 267, 268
hemodynamic effects in healthy volunteers, 263–268
vasovagal responses, 268
- Singlet oxygen, guggulsterone and, 663
- Sinoatrial node fibrosis, hypertrophic cardiomyopathy and, 96
- Sinus node function, abnormalities in hypertrophic cardiomyopathy patients, 96
- Sinus rhythm
alcoholic cardiomyopathy, 92
arrhythmia management in hypertrophic cardiomyopathy, 95–96, 98
digoxin with ACE inhibitors, 116
- Sinus tachycardia, beta-blockers for dilated cardiomyopathy, 83, 84
- Skeletal muscle fatigue, beta blockers, 568
- Skeletal muscle metabolism, congestive heart failure, peripheral factors in management of, 75, 78
- SKF-525A, 706
- SKF 86466, 24
- SK&F86466, 28, 33, 34–35, 37
- Small vessel disease, diabetic cardiomyopathy, 65–66
- Smoking
Dr. Robertson's reply to Dr. Kaplan, 675
- Eskimos and incidence of atherosclerosis, 180, 188
sudden death and alcoholic cardiomyopathy, 89
- Smooth muscle cell, relaxants, 701–702, 703, 704
- S-nitroso-N-acetylpeni-cillamine (SNAP), 495–496
- S-nitrosothiols, 493
- Sodium
in arterial walls, and vasodilation in CHF patients, 77, 79–80
low-salt diet, doxazosin vs. nitrendipine efficacy, 473–476
salt intake, hypertension and cultured societies related, 425
- Sodium channel activation, SDZ 218–135 as positive inotropic agent, 235–243
- Sodium excretion, moxonidine effect in rats, 43–47
- Sodium nitroprusside, 606
action mechanisms, 701
- Sodium-proton exchange, 536
- Sodium restriction
dilated cardiomyopathy treatment, 83
hypertension and, 669
- Sodium retention, imidazolines, 36
- SOLVD study. *See* Studies of Left Ventricular Dysfunction (SOLVD) study
- Spearman rank correlation coefficient, 148
- SPECT images, 387
- Sphericity index, 458
- Spironolactone, for dilated cardiomyopathy, 84
- SPRINT database, 549, 553
- SPRINT I study, 408
- SPRINT II study, 408
- Stable angina
acadesine effect on exercise-induced myocardial ischemia, 193–196
oral nitrates for, 611–620
pathophysiology of, 612
- Staphylokinase, thrombolytic agents, 801–809
- Starling mechanism, 75, 302
- Starling's law, 582
- Static pressure, 448
- Stepped care, 675
approach, VA study, 7
- Stimulated platelet PAI-1, 709
- Streptozotocin, inducing diabetes, 67, 69
- Stress, effects on right ventricular function, 399–400
- Stress-redistribution-reinjection thallium imaging, 384–385
- Stroke
as result of hypertension, 7
risk, antihypertensive treatment and, 667, 669
sympathetic overactivity, 18
- Stroke volume index, epanoprol in coronary artery disease, 215, 217
- Stroke work index, epanoprol in coronary artery disease, 213, 214, 215, 216
- Studies of Left Ventricular Dysfunction (SOLVD) study, 299, 456
ACE inhibitors and neurohormonal mechanisms, 685, 686, 687–688, 689, 690, 691
alcoholic cardiomyopathy, 92
angiotensin converting enzyme inhibition in CHF patients, 80
aspirin diminishing ACE inhibitor benefits, 112
enalapril, 434
enalapril for heart failure, 112
Prevention Trial, neurohormones in LV dysfunction, 314, 315
- Stunning
calcium antagonists and amelioration of, 536–539
calcium antagonist usefulness, 533–539
calcium ions role, 534
characteristics, 298
compared to hibernation, 372
components (four), 533, 534
contractile dysfunction accompanied by an upregulation of sarcoplasmic reticulum Ca^{2+} ATPase gene, 461, 462, 464–467
definition, 534
diastolic dysfunction, 298–299

- ischemic right ventricular dysfunction, 393, 396, 401, 402
 left ventricular dysfunction in patients, 371–377
 losses of midwall and epicardial collagen, and increases in collagenase activity in dogs, 309, 310
 LV dysfunction after myocardial infarction and prognosis, 319–320, 324
 nisoldipine (IV) effects and functional recovery from, 350
 positron emission tomography imaging, 386
 role of phosphatidylinositol cycle, 536
 sestamibi imaging, 385
 voltage-sensitive calcium channels, 535–536
- Subclinical, abnormalities of left ventricular function, 89
 Substance P, 440, 441, 603
 Sudden death
 amiodarone for prevention in hypertrophic cardiomyopathy, 95
 interactions and risks after infarction, 335, 336, 338, 339, 340, 341
 left ventricular dysfunction after myocardial infarction and prognosis, 323
 left ventricular hypertrophy as risk factor, 16
 LVH associated with increased morbidity and mortality, 557–561
 risk reduction with beta-blockers, 85
 with hypertrophic cardiomyopathy, 95, 96–98
 Sulphydryl depletion hypothesis, 491–498, 494
 Sulphydryl (SG) group, 704
 Sulfbromophthalein (SBP), 705, 706
 Superoxide dismutase (SOD), combined with free iron, 105
 Superquantum interference device (SQUID), to detect iron levels in large organs, 106
 Supraventricular arrhythmias
 hypertrophic cardiomyopathy and, 95–99
 verapamil therapy after an AMI, 150–151
 Supraventricular tachycardia
 DAVIT II trial, 148–151
 hypertrophic cardiomyopathy, 95–99
 Survival and Ventricular Enlargement (SAVE) trial, 239, 324, 458, 470, 688, 689, 690
 ACE inhibition in CHF patients, 80
 ACE inhibitors' use after infarction studied, 113
 aspirin diminishing ACE inhibitor benefits, 112
 beta-blockers with ACE inhibition for high risk post MI patient, 116
 captopril and infarct-related heart failure, 433, 434–435, 436
 significance, 435–436
- Swedish STOP trial, 667
 Sydnonimines, 606
 Sympathetic nervous system
 alpha-1 receptors in syndrome X, 221–225
 definition of heart failure and congestive cardiac failure, 449
 salt intake effect, 429–430
 Sympathetic overactivity, moxonidine as a selective I₁-imidazoline agonist, 27
 Sympathetic tone
 discharge from central nervous system decreased, 13
 overactivity and overreactivity in hypertension, 11–18
 Sympatholytic, imidazoline I₁ receptors in the RVLM mediating blood pressure reduction, 21–26
 Syncope, with hypertrophic cardiomyopathy, 96, 97, 98
 Syndrome X, 8, 221–225
 Systemic vascular resistance, epanolol in coronary artery disease, 213, 214, 218
 Systolic dysfunction
 alcoholic cardiomyopathy, 89–90
 calcium antagonists not as benefit, 302
 iron overload cardiomyopathy, 101, 102, 104–105, 106
 preceded by diastolic dysfunction in diabetes, 66, 67
- Tachycardia, 12
 Target organ damage (TOD), 666
 Target-organ disease, 8
 Tension time index, 481
 Tetrahydrobiopterin, 603
 Thalassemia, iron overload cardiomyopathy, 102, 106, 107
 Thallium-201 imaging, 384–385
 Thiazides, 123–126
 action onset and duration after oral administration, 125
 for hypertension, combination therapy, 7
 as treatment of hypertension, 668, 669, 670
 Thiazoleylethylamine, 36
 Three-vessel coronary artery disease, epanolol therapy, 211–218
 Threshold, electrical fibrillation threshold time course during myocardial ischemia and fibrillation, calcium role, 877–878
 Thrombolysis
 adjuvant therapy (captopril, metoprolol and their combination in acute myocardial infarction, 875–876 and metoprolol (oral) in acute infarction in dogs, 479–486
 Thrombolytic therapy
 ACE inhibitors after infarction studied, 113
 ACE inhibitor trials and, 470–471
- endothelin levels, 591
 ischemic RV dysfunction, 402
 novel agents, 801–809
 Thromboxane A₂ synthesis, 704
 Tiapamil
 second generation drug, 356
 vs. verapamil, 567
 Timolol, 323–324
 Tiotidine, 29, 36
²¹⁰Tl, 387, 389
 Tocainide, 116
 Tolazoline, 28, 37
 Tolbutamide, 67
 Tolerability, felodipine ER and diltiazem SR as monotherapy for hypertension, 845–848
 Tolerance
 nitrates in silent ischemia, 727–732
 nitrate tolerance mechanisms, 489–497
 transdermal nitrates for stable angina, 625–630
 Torasemide, 125–126
 Total peripheral vascular resistance (TPR), simendan effect in healthy volunteers, 264
 t-PA, thrombolytic agents, 801–809
 Transdermal nitrates, in silent ischemia, 727–732
 Transient asymptomatic ischemia, LV dysfunction after myocardial infarction and prognosis, 319, 320–321, 323–324
 Transient inward current, perindoprilat in rabbit hearts, 647–650
 Transplants, maximum vasodilation in treatment of heart failure and DCM, 85–86, 87
 Treatment and Prevention Trials of Studies of Left Ventricular Dysfunction, 383
 Treatment of Mild Hypertension Study group (TOMHS), 430, 559–560, 673
 TRENT study, 408
 Triglycerides, guggulipid decreasing of blood lipoproteins, 659–664
 T-type (LVA) channels, 354
 Two-vessel coronary artery disease, epanolol therapy, 211–218
 Type I collagen, fibrous matrix function, 306–307, 308, 310
 Type I diabetes, diabetic cardiomyopathy, 66–67
 Type 2 calcium channel gene (CaCh2), 354
 Type II diabetes, diabetic cardiomyopathy, 66–67
 Type III collagen, fibrous matrix function, 306
- U46619, 142
 Ubiquitin, 465, 466
 US Hypertension Detection and Follow-up Program (HDFP), 666, 667, 668, 670, 673, 675

U.S. Joint National Committee, 665, 666, 668, 669
 Unstable angina
 before LV dysfunction, 373–374
 before open heart surgery, 374–375
 DEFIANT study of nisoldipine post-myocardial infarction, 410
 endothelin levels, 590
 nitrates for, 719–724
 prognostic factor after acute myocardial infarction, 320–321, 323
 Unstimulated, basal NO release, 601
 Vanadate, 69
 Vascular changes, and congestive heart failure, 75, 77–78
 Vascular smooth muscle cells, diltiazem inhibitions of DNA synthesis and Ca^{2+} uptake induced by insulin, IGF-I, and PDGF, 861–869
 Vascular smooth muscles, relaxants, 701–702
 Vascular volume, nitrates in congestive heart failure, 501–505
 Vasoactive intestinal polypeptide, 603
 Vasodilator Heart Failure Trial, *See* Veterans Administration Cooperative Vasodilator Heart Failure Trials I and II
 Vasodilator reserve, blood pressure lowering effect in arterial hypertension, 169–170
 Vasodilators, 83, 84–85, 87
 Vasopressin, 444, 448–449, 603
 Vein graft, fish oil effective in preventing accelerated graft intima proliferation, 179, 184–186, 187–188
 Ventricular arrhythmias
 adjuvant therapy (captopril, metoprolol, and their combination) in myocardial infarction, 875–876
 beta-blockers for dilated cardiomyopathy, 88, 85–86, 87
 interactions and risks after infarction, 335, 336, 337, 338, 339, 340–341
 LV dysfunction after myocardial in-

farction and prognosis, 323
 with reperfusion injury, 534
 Ventricular dysfunction
 assessment by nuclear cardiology, 381–389
 due to hibernation, 375–377
 Ventricular dysrhythmias, LVH linked to, 557–561
 Ventricular ectopy
 LVH linked to, 557–561
 sudden death and, 559
 Ventricular fibrillation, 337
 electrical fibrillation threshold time course, calcium role, 877–878
 Ventricular function, senescent heart overloading and failure, 581–585
 Ventricular premature beats, 340
 Ventricular premature complexes (VPC), verapamil effect following an acute myocardial infarction, 147–151
 Ventricular septal defect (VSD), hydralazine for afterload reduction in children, 161–166
 Ventricular tachycardia, 86, 87, 95–99
 Verapamil, 724
 antianginal mechanism and negative inotropic effect, 353
 binding sites, 565, 566, 568
 cardiovascular ratio, 356
 contraindicated for post myocardial infarction heart failure, 116
 DAVIT II study, 147–151, 408
 diastolic dysfunction, 299
 first generation drug, 356
 for dilated cardiomyopathy, 84
 for hypertrophic cardiomyopathy, 98
 hemodynamic effects, 569–573
 in myocardial infarction, 543–547
 interaction with alcohol for alcoholic cardiomyopathy, 93
 ischemia role in postinfarction heart failure, based on verapamil use in DAVIT II, 823–827
 isoveramil added after onset of reperfusion to lessen stunning, 537
 no inhibitory action, 357–358

positive response in patients with LV diastolic dysfunction, 302
 postinfarct mortality positive trial, 566
 protective effect in experimental diabetic cardiomyopathy, 65, 69
 prototype with derivatives and their differences, 567
 reducing left ventricular mass, 554
 unstable angina and, 719
 Vernarinone (OPC-8212), 84, 765
 Vesnarinone Study Group, 765
 Veterans Administration (VA) studies, 7, 667, 673
 V-HeFT trials (I and II), 120, 505, 685, 688–690
 Viable myocardium, 384
 Voltage-operated calcium channels, cardioselectivity of calcium antagonists, 353, 358
 Volume expansion, 8
 Wall motion score index (WMS), 320, 321
 Warfarin, 93, 117
 Water-perfusable tissue index, 387
 Weckenbach blocks, 583
 White coat hypertension, 15
 Whites, salt sensitivity, 427
 WHO/ISH Committee, 665–669
 WHO study I and II, 735
 Wilcoxon-Mann-Whitney two-sample test, 202, 736
 Wilcoxon signed rank test, 148
 Wolff-Parkinson-White syndrome disopyramide therapy and impotence, 277
 hypertrophic cardiomyopathy and, 96
 Women, diabetic cardiomyopathy, 65
 Xamoterol Severe Heart Failure Study, 434, 690
 Yohimbine, 28, 35, 37, 38, 43
 Zaprinast, 707
 Z-guggulsterone, 659, 663, 664

